Biological properties of Moringa oleifera: A systematic review of the last decade

Biological properties of Moringa oleifera: A... | F1000Research "use strict";function _typeof(t){return(_typeof="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&"function"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?"symbol":typeof t})(t)}!function(){var t=function(){var t,e,o=[],n=window,r=n;for(;r;){try{if(r.frames.__tcfapiLocator){t=r;break}}catch(t){}if(r===n.top)break;r=r.parent}t||(!function t(){var e=n.document,o=!!n.frames.__tcfapiLocator;if(!o)if(e.body){var r=e.createElement("iframe");r.style.cssText="display:none",r.name="__tcfapiLocator",e.body.appendChild(r)}else setTimeout(t,5);return!o}(),n.__tcfapi=function(){for(var t=arguments.length,n=new Array(t),r=0;r 3&&2===parseInt(n[1],10)&&"boolean"==typeof n[3]&&(e=n[3],"function"==typeof n[2]&&n[2]("set",!0)):"ping"===n[0]?"function"==typeof n[2]&&n[2]({gdprApplies:e,cmpLoaded:!1,cmpStatus:"stub"}):o.push(n)},n.addEventListener("message",(function(t){var e="string"==typeof t.data,o={};if(e)try{o=JSON.parse(t.data)}catch(t){}else o=t.data;var n="object"===_typeof(o)&&null!==o?o.__tcfapiCall:null;n&&window.__tcfapi(n.command,n.version,(function(o,r){var a={__tcfapiReturn:{returnValue:o,success:r,callId:n.callId}};t&&t.source&&t.source.postMessage&&t.source.postMessage(e?JSON.stringify(a):a,"*")}),n.parameter)}),!1))};"undefined"!=typeof module?module.exports=t:t()}(); dataLayer = dataLayer || []; // Standard GTM initialization - Google Consent Mode handles consent automatically (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+ '>m_auth=hzk0Vc3qFsQYhCrIoHz68A>m_preview=env-1>m_cookies_win=x';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MWFK8L5J'); ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}}; ;NREUM.loader_config={accountID:"438030",trustKey:"438030",agentID:"772317073",licenseKey:"97f8f67f26",applicationID:"772317073"} ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"97f8f67f26",applicationID:"772317073",sa:1} ;/*! For license information please see nr-loader-spa-1.236.0.min.js.LICENSE.txt */ (()=>{"use strict";var e,t,r={5763:(e,t,r)=>{r.d(t,{P_:()=>l,Mt:()=>g,C5:()=>s,DL:()=>v,OP:()=>T,lF:()=>D,Yu:()=>y,Dg:()=>h,CX:()=>c,GE:()=>b,sU:()=>_});var n=r(8632),i=r(9567);const o={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.D)(t,o),(0,n.Qy)(e,a[e],"info")}var u=r(7056);const d=()=>{const e={blockSelector:"[data-nr-block]",maskInputOptions:{password:!0}};return{allow_bfcache:!0,privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,enabled:!0,harvestTimeSeconds:10},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10},metrics:{enabled:!0},page_action:{enabled:!0,harvestTimeSeconds:30},page_view_event:{enabled:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1},session_trace:{enabled:!0,harvestTimeSeconds:10},harvest:{tooManyRequestsDelay:60},session_replay:{enabled:!1,harvestTimeSeconds:60,sampleRate:.1,errorSampleRate:.1,maskTextSelector:"*",maskAllInputs:!0,get blockClass(){return"nr-block"},get ignoreClass(){return"nr-ignore"},get maskTextClass(){return"nr-mask"},get blockSelector(){return e.blockSelector},set blockSelector(t){e.blockSelector+=",".concat(t)},get maskInputOptions(){return e.maskInputOptions},set maskInputOptions(t){e.maskInputOptions={...t,password:!0}}},spa:{enabled:!0,harvestTimeSeconds:10}}},f={};function l(e){if(!e)throw new Error("All configuration objects require an agent identifier!");if(!f[e])throw new Error("Configuration for ".concat(e," was never set"));return f[e]}function h(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");f[e]=(0,i.D)(t,d()),(0,n.Qy)(e,f[e],"config")}function g(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");var r=l(e);if(r){for(var n=t.split("."),i=0;i {r.d(t,{D:()=>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=>{r.d(t,{Re:()=>i,gF:()=>o,q4:()=>n});const n="1.236.0",i="PROD",o="CDN"},385:(e,t,r)=>{r.d(t,{FN:()=>a,IF:()=>u,Nk:()=>f,Tt:()=>s,_A:()=>o,il:()=>n,pL:()=>c,v6:()=>i,w1:()=>d});const n="undefined"!=typeof window&&!!window.document,i="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),o=n?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a=""+o?.location,s=/iPad|iPhone|iPod/.test(navigator.userAgent),c=s&&"undefined"==typeof SharedWorker,u=(()=>{const e=navigator.userAgent.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),d=Boolean(n&&window.document.documentMode),f=!!navigator.sendBeacon},1117:(e,t,r)=>{r.d(t,{w:()=>o});var n=r(50);const i={agentIdentifier:"",ee:void 0};class o{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=>{let[t,r]=e;Object.keys(i).includes(t)&&(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=>{r.d(t,{L:()=>d,R:()=>c});var n=r(2177),i=r(1284),o=r(4322),a=r(3325);const s={};function c(e,t){const r={staged:!1,priority:a.p[t]||0};u(e),s[e].get(t)||s[e].set(t,r)}function u(e){e&&(s[e]||(s[e]=new Map))}function d(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"",t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"feature";if(u(e),!e||!s[e].get(t))return a(t);s[e].get(t).staged=!0;const r=[...s[e]];function a(t){const r=e?n.ee.get(e):n.ee,a=o.X.handlers;if(r.backlog&&a){var s=r.backlog[t],c=a[t];if(c){for(var u=0;s&&u {let[t,r]=e;return r.staged}))&&(r.sort(((e,t)=>e[1].priority-t[1].priority)),r.forEach((e=>{let[t]=e;a(t)})))}function f(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],o=e[3],a=e[2];i.apply(o,a)}}))}},2177:(e,t,r)=>{r.d(t,{c:()=>f,ee:()=>u});var n=r(8632),i=r(2210),o=r(1284),a=r(5763),s="nr@context";let c=(0,n.fP)();var u;function d(){}function f(e){return(0,i.X)(e,s,l)}function l(){return new d}function h(){u.aborted=!0,u.backlog={}}c.ee?u=c.ee:(u=function e(t,r){var n={},c={},f={},g=!1;try{g=16===r.length&&(0,a.OP)(r).isolatedBacklog}catch(e){}var p={on:b,addEventListener:b,removeEventListener:y,emit:v,get:x,listeners:w,context:m,buffer:A,abort:h,aborted:!1,isBuffering:E,debugId:r,backlog:g?{}:t&&"object"==typeof t.backlog?t.backlog:{}};return p;function m(e){return e&&e instanceof d?e:e?(0,i.X)(e,s,l):l()}function v(e,r,n,i,o){if(!1!==o&&(o=!0),!u.aborted||i){t&&o&&t.emit(e,r,n);for(var a=m(n),s=w(e),d=s.length,f=0;fn,p:()=>i});var n=r(2177).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=>{r.d(t,{X:()=>o});var n=r(5546);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.E,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.E);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3239:(e,t,r)=>{r.d(t,{bP:()=>s,iz:()=>c,m$:()=>a});var n=r(385);let i=!1,o=!1;try{const e={get passive(){return i=!0,!1},get signal(){return o=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function a(e,t){return i||o?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;window.addEventListener(e,t,a(r,n))}function c(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;document.addEventListener(e,t,a(r,n))}},4402:(e,t,r)=>{r.d(t,{Ht:()=>u,M:()=>c,Rl:()=>a,ky:()=>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=>"x"===e?o(t,++r).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(31)));const a=[];for(var s=0;s {r.d(t,{Bq:()=>n,Hb:()=>o,oD:()=>i});const n="NRBA",i=144e5,o=18e5},7894:(e,t,r)=>{function n(){return Math.round(performance.now())}r.d(t,{z:()=>n})},7243:(e,t,r)=>{r.d(t,{e:()=>o});var n=r(385),i={};function o(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,o={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return o}o.port=t.port;var a=t.href.split("://");!o.port&&a[1]&&(o.port=a[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===a[0]?"443":"80"),o.hostname=t.hostname||r.hostname,o.pathname=t.pathname,o.protocol=a[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&&t.port===r.port;return o.sameOrigin=s&&(!t.hostname||c),"/"===o.pathname&&(i[e]=o),o}},50:(e,t,r)=>{function n(e,t){"function"==typeof console.warn&&(console.warn("New Relic: ".concat(e)),t&&console.warn(t))}r.d(t,{Z:()=>n})},2587:(e,t,r)=>{r.d(t,{N:()=>c,T:()=>u});var n=r(2177),i=r(5546),o=r(8e3),a=r(3325);const s={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]};function c(e,t){const r=n.ee.get(t);e&&"object"==typeof e&&(Object.entries(e).forEach((e=>{let[t,n]=e;void 0===u[t]&&(s[t]?s[t].forEach((e=>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&&(0,i.p)("feat-"+t,[],void 0,void 0,r),u[t]=Boolean(n))})),Object.keys(s).forEach((e=>{void 0===u[e]&&(s[e]?.forEach((t=>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),u[e]=!1)})),(0,o.L)(t,a.D.pageViewEvent))}const u={}},2210:(e,t,r)=>{r.d(t,{X:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=>{r.d(t,{D:()=>n});const n=(e,t)=>Object.entries(e||{}).map((e=>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=>{r.d(t,{P:()=>o});var n=r(2177);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=>{r.d(t,{K:()=>a,b:()=>o});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.bP)("load",e,t)}function a(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=>{r.d(t,{EZ:()=>u,Qy:()=>c,ce:()=>o,fP:()=>a,gG:()=>d,mF:()=>s});var n=r(7894),i=r(385);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&&(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=a();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=a();const o=i.initializedAgents||{},s=o[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...o,[e]:{...s,[r]:t}},i}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},7956:(e,t,r)=>{r.d(t,{N:()=>i});var n=r(3239);function i(e){let t=arguments.length>1&&void 0!==arguments[1]&&arguments[1],r=arguments.length>2?arguments[2]:void 0,i=arguments.length>3?arguments[3]:void 0;return void(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"==document.visibilityState&&e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=>{r.d(t,{em:()=>v,u5:()=>N,QU:()=>S,_L:()=>I,Gm:()=>L,Lg:()=>M,gy:()=>U,BV:()=>Q,Kf:()=>ee});var n=r(2177);const i="nr@original";var o=Object.prototype.hasOwnProperty,a=!1;function s(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");var a,s,c,u="-"===n.charAt(0);for(c=0;c 2?n-2:0),o=2;o {r(A[T],e,w),r(E[T],e,w)})),r(l._A,"fetch",y),t.on(y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(y+"done",[null,r],n)}else t.emit(y+"done",[e],n)})),t}const O={},j=["pushState","replaceState"];function S(e){const t=function(e){return(e||n.ee).get("history")}(e);return!l.il||O[t.debugId]++||(O[t.debugId]=1,s(t).inPlace(window.history,j,"-")),t}var P=r(3239);const C={},R=["appendChild","insertBefore","replaceChild"];function I(e){const t=function(e){return(e||n.ee).get("jsonp")}(e);if(!l.il||C[t.debugId])return t;C[t.debugId]=!0;var r=s(t),i=/[?&](?:callback|cb)=([^&#]+)/,o=/(.*)\.([^.]+)/,a=/^(\w+)(\.|$)(.*)$/;function c(e,t){var r=e.match(a),n=r[1],i=r[3];return i?c(i,t[n]):t[n]}return r.inPlace(Node.prototype,R,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var n=(a=e.src,s=a.match(i),s?s[1]:null);var a,s;if(!n)return;var u=function(e){var t=e.match(o);if(t&&t.length>=3)return{key:t[2],parent:c(t[1],window)};return{key:e,parent:window}}(n);if("function"!=typeof u.parent[u.key])return;var d={};function f(){t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}function l(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",f,(0,P.m$)(!1)),e.addEventListener("error",l,(0,P.m$)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}var k=r(5763);const H={};function L(e){const t=function(e){return(e||n.ee).get("mutation")}(e);if(!l.il||H[t.debugId])return t;H[t.debugId]=!0;var r=s(t),i=k.Yu.MO;return i&&(window.MutationObserver=function(e){return this instanceof i?new i(r(e,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype),t}const z={};function M(e){const t=function(e){return(e||n.ee).get("promise")}(e);if(z[t.debugId])return t;z[t.debugId]=!0;var r=n.c,o=s(t),a=k.Yu.PR;return a&&function(){function e(r){var n=t.context(),i=o(r,"executor-",n,null,!1);const s=Reflect.construct(a,[i],e);return t.context(s).getCtx=function(){return n},s}l._A.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return a.toString()},Object.setPrototypeOf(e,a),["all","race"].forEach((function(r){const n=a[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=a[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=a.prototype;const n=a.prototype.then;a.prototype.then=function(){var e=this,i=r(e);i.promise=e;for(var a=arguments.length,s=new Array(a),c=0;c e())),t};function m(e,t){i.inPlace(t,["onreadystatechange"],"fn-",E)}function b(){var e=this,t=r.context(e);e.readyState>3&&!t.resolved&&(t.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,f,"fn-",E)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,p),p.prototype=o.prototype,i.inPlace(p.prototype,J,"-xhr-",E),r.on("send-xhr-start",(function(e,t){m(e,t),function(e){h.push(e),a&&(y?y.then(A):u?u(A):(w=-w,x.data=w))}(t)})),r.on("open-xhr-start",m),a){var y=c&&c.resolve();if(!u&&!c){var w=1,x=document.createTextNode(w);new a(A).observe(x,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&&e[0].type===d||A()}));function A(){for(var e=0;e {r.d(t,{t:()=>n});const n=r(3325).D.ajax},6660:(e,t,r)=>{r.d(t,{A:()=>i,t:()=>n});const n=r(3325).D.jserrors,i="nr@seenError"},3081:(e,t,r)=>{r.d(t,{gF:()=>o,mY:()=>i,t9:()=>n,vz:()=>s,xS:()=>a});const n=r(3325).D.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageAction},7633:(e,t,r)=>{r.d(t,{Dz:()=>i,OJ:()=>a,qw:()=>o,t9:()=>n});const n=r(3325).D.pageViewEvent,i="firstbyte",o="domcontent",a="windowload"},9251:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageViewTiming},3614:(e,t,r)=>{r.d(t,{BST_RESOURCE:()=>i,END:()=>s,FEATURE_NAME:()=>n,FN_END:()=>u,FN_START:()=>c,PUSH_STATE:()=>d,RESOURCE:()=>o,START:()=>a});const n=r(3325).D.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState"},7836:(e,t,r)=>{r.d(t,{BODY:()=>A,CB_END:()=>E,CB_START:()=>u,END:()=>x,FEATURE_NAME:()=>i,FETCH:()=>_,FETCH_BODY:()=>v,FETCH_DONE:()=>m,FETCH_START:()=>p,FN_END:()=>c,FN_START:()=>s,INTERACTION:()=>l,INTERACTION_API:()=>d,INTERACTION_EVENTS:()=>o,JSONP_END:()=>b,JSONP_NODE:()=>g,JS_TIME:()=>T,MAX_TIMER_BUDGET:()=>a,REMAINING:()=>f,SPA_NODE:()=>h,START:()=>w,originalSetTimeout:()=>y});var n=r(5763);const i=r(3325).D.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",f="remaining",l="interaction",h="spaNode",g="jsonpNode",p="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=n.Yu.ST,w="-start",x="-end",A="-body",E="cb"+x,T="jsTime",_="fetch"},5938:(e,t,r)=>{r.d(t,{W:()=>o});var n=r(5763),i=r(2177);class o{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},9144:(e,t,r)=>{r.d(t,{j:()=>m});var n=r(3325),i=r(5763),o=r(5546),a=r(2177),s=r(7894),c=r(8e3),u=r(3960),d=r(385),f=r(50),l=r(3081),h=r(8632);function g(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId"].forEach((t=>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i 1?r-1:0),i=1;i {e.exposed&&e.api[t]&&o.push(e.api[t](...n))})),o.length>1?o:o[0]}(t,...n)}}))}var p=r(2587);function m(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},m=arguments.length>2?arguments[2]:void 0,v=arguments.length>3?arguments[3]:void 0,{init:b,info:y,loader_config:w,runtime:x={loaderType:m},exposed:A=!0}=t;const E=(0,h.gG)();y||(b=E.init,y=E.info,w=E.loader_config),(0,i.Dg)(e,b||{}),(0,i.GE)(e,w||{}),(0,i.sU)(e,x),y.jsAttributes??={},d.v6&&(y.jsAttributes.isWorker=!0),(0,i.CX)(e,y),g();const T=function(e,t){t||(0,c.R)(e,"api");const h={};var g=a.ee.get(e),p=g.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,o){const a=(0,i.C5)(e);return null===r?delete a.jsAttributes[t]:(0,i.CX)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),x(m,n,!0,o||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=>h[e]=x(m,e,!0,"api"))),h.addPageAction=x(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=x(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,x(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,f.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of was provided."))}else(0,f.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,f.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of was provided."))},h.interaction=function(){return(new y).get()};var w=y.prototype={createTracer:function(e,t){var r={},i=this,a="function"==typeof t;return(0,o.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,g),function(){if(p.emit((a?"":"no-")+"fn-start",[(0,s.z)(),i,a],r),a)try{return t.apply(this,arguments)}catch(e){throw p.emit("fn-err",[arguments,this,"string"==typeof e?new Error(e):e],r),e}finally{p.emit("fn-end",[(0,s.z)()],r)}}}};function x(e,t,r,i){return function(){return(0,o.p)(l.xS,["API/"+t+"/called"],void 0,n.D.metrics,g),i&&(0,o.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,g),r?void 0:this}}function A(){r.e(439).then(r.bind(r,7438)).then((t=>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=>(0,f.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{w[e]=x(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&&(e=new Error(e)),(0,o.p)(l.xS,["API/noticeError/called"],void 0,n.D.metrics,g),(0,o.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,g)},d.il?(0,u.b)((()=>A()),!0):A(),h}(e,v);return(0,h.Qy)(e,T,"api"),(0,h.Qy)(e,A,"exposed"),(0,h.EZ)("activatedFeatures",p.T),T}},3325:(e,t,r)=>{r.d(t,{D:()=>n,p:()=>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>(({78:"page_action-aggregate",147:"metrics-aggregate",242:"session-manager",317:"jserrors-aggregate",348:"page_view_timing-aggregate",412:"lazy-feature-loader",439:"async-api",538:"recorder",590:"session_replay-aggregate",675:"compressor",733:"session_trace-aggregate",786:"page_view_event-aggregate",873:"spa-aggregate",898:"ajax-aggregate"}[e]||e)+"."+{78:"ac76d497",147:"3dc53903",148:"1a20d5fe",242:"2a64278a",317:"49e41428",348:"bd6de33a",412:"2f55ce66",439:"30bd804e",538:"1b18459f",590:"cf0efb30",675:"ae9f91a8",733:"83105561",786:"06482edd",860:"03a8b7a5",873:"e6b09d52",898:"998ef92b"}[e]+"-1.236.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d {s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},h=setTimeout(l.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=l.bind(null,s.onerror),s.onload=l.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.j=364,i.p="https://js-agent.newrelic.com/",(()=>{var e={364:0,953:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u {i.r(o);var e=i(3325),t=i(5763);const r=Object.values(e.D);function n(e){const n={};return r.forEach((r=>{n[r]=function(e,r){return!1!==(0,t.Mt)(r,"".concat(e,".enabled"))}(r,e)})),n}var a=i(9144);var s=i(5546),c=i(385),u=i(8e3),d=i(5938),f=i(3960),l=i(50);class h extends d.W{constructor(e,t,r){let n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=n,this.abortHandler,this.featAggregate,this.onAggregateImported,n&&(0,u.R)(e,r)}importAggregator(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate||!this.auto)return;const r=c.il&&!0===(0,t.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let t;try{if(r){const{setupAgentSession:e}=await Promise.all([i.e(860),i.e(242)]).then(i.bind(i,3228));t=e(this.agentIdentifier)}}catch(e){(0,l.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",e)}try{if(!this.shouldImportAgg(this.featureName,t))return void(0,u.L)(this.agentIdentifier,this.featureName);const{lazyFeatureLoader:r}=await i.e(412).then(i.bind(i,8582)),{Aggregate:o}=await r(this.featureName,"aggregate");this.featAggregate=new o(this.agentIdentifier,this.aggregator,e),n(!0)}catch(e){(0,l.Z)("Downloading and initializing ".concat(this.featureName," failed..."),e),this.abortHandler?.(),n(!1)}};c.il?(0,f.b)((()=>o()),!0):o()}shouldImportAgg(r,n){return r!==e.D.sessionReplay||!1!==(0,t.Mt)(this.agentIdentifier,"session_trace.enabled")&&(!!n?.isNew||!!n?.state.sessionReplay)}}var g=i(7633),p=i(7894);class m extends h{static featureName=g.t9;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(super(r,n,g.t9,i),("undefined"==typeof PerformanceNavigationTiming||c.Tt)&&"undefined"!=typeof PerformanceTiming){const n=(0,t.OP)(r);n[g.Dz]=Math.max(Date.now()-n.offset,0),(0,f.K)((()=>n[g.qw]=Math.max((0,p.z)()-n[g.Dz],0))),(0,f.b)((()=>{const t=(0,p.z)();n[g.OJ]=Math.max(t-n[g.Dz],0),(0,s.p)("timing",["load",t],void 0,e.D.pageViewTiming,this.ee)}))}this.importAggregator()}}var v=i(1117),b=i(1284);class y extends v.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var o=this.getBucket(e,t,r,i);return o.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,b.D)(e,(function(e,r){t[e]=w(r,t[e])})),t}(n,o.metrics),o}merge(e,t,r,n,i){var o=this.getBucket(e,t,n,i);if(o.metrics){var a=o.metrics;a.count+=r.count,(0,b.D)(r,(function(e,t){if("count"!==e){var n=a[e],i=r[e];i&&!i.c?a[e]=w(i.t,n):a[e]=function(e,t){if(!t)return e;t.c||(t=x(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,a[e])}}))}else o.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=w(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&&(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&&this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i t.max&&(t.max=e),e 2&&void 0!==arguments[2])||arguments[2];super(e,r,j.t,n),c.il&&((0,t.OP)(e).initHidden=Boolean("hidden"===document.visibilityState),(0,N.N)((()=>(0,s.p)("docHidden",[(0,p.z)()],void 0,j.t,this.ee)),!0),(0,O.bP)("pagehide",(()=>(0,s.p)("winPagehide",[(0,p.z)()],void 0,j.t,this.ee))),this.importAggregator())}}var P=i(3081);class C extends h{static featureName=P.t9;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,P.t9,r),this.importAggregator()}}var R,I=i(2210),k=i(1214),H=i(2177),L={};try{R=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(L.console=!0,-1!==R.indexOf("dev")&&(L.dev=!0),-1!==R.indexOf("nr_dev")&&(L.nrDev=!0))}catch(e){}function z(e){try{L.console&&z(e)}catch(e){}}L.nrDev&&H.ee.on("internal-error",(function(e){z(e.stack)})),L.dev&&H.ee.on("fn-err",(function(e,t,r){z(r.stack)})),L.dev&&(z("NR AGENT IN DEVELOPMENT MODE"),z("flags: "+(0,b.D)(L,(function(e,t){return e})).join(", ")));var M=i(6660);class B extends h{static featureName=M.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,M.t,i),this.skipNext=0;try{this.removeOnAbort=new AbortController}catch(e){}const o=this;o.ee.on("fn-start",(function(e,t,r){o.abortHandler&&(o.skipNext+=1)})),o.ee.on("fn-err",(function(t,r,n){o.abortHandler&&!n[M.A]&&((0,I.X)(n,M.A,(function(){return!0})),this.thrown=!0,(0,s.p)("err",[n,(0,p.z)()],void 0,e.D.jserrors,o.ee))})),o.ee.on("fn-end",(function(){o.abortHandler&&!this.thrown&&o.skipNext>0&&(o.skipNext-=1)})),o.ee.on("internal-error",(function(t){(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,o.ee)})),this.origOnerror=c._A.onerror,c._A.onerror=this.onerrorHandler.bind(this),c._A.addEventListener("unhandledrejection",(t=>{const r=function(e){let t="Unhandled Promise Rejection: ";if(e instanceof Error)try{return e.message=t+e.message,e}catch(t){return e}if(void 0===e)return new Error(t);try{return new Error(t+(0,D.P)(e))}catch(e){return new Error(t)}}(t.reason);(0,s.p)("err",[r,(0,p.z)(),!1,{unhandledPromiseRejection:1}],void 0,e.D.jserrors,this.ee)}),(0,O.m$)(!1,this.removeOnAbort?.signal)),(0,k.gy)(this.ee),(0,k.BV)(this.ee),(0,k.em)(this.ee),(0,t.OP)(r).xhrWrappable&&(0,k.Kf)(this.ee),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}onerrorHandler(t,r,n,i,o){"function"==typeof this.origOnerror&&this.origOnerror(...arguments);try{this.skipNext?this.skipNext-=1:(0,s.p)("err",[o||new F(t,r,n),(0,p.z)()],void 0,e.D.jserrors,this.ee)}catch(t){try{(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,this.ee)}catch(e){}}return!1}}function F(e,t,r){this.message=e||"Uncaught error with no additional information",this.sourceURL=t,this.line=r}let U=1;const q="nr@id";function G(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===c._A?0:(0,I.X)(e,q,(function(){return U++}))}function V(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,D.P)(e).length}catch(e){return}}}var X=i(7243);class W{constructor(e){this.agentIdentifier=e,this.generateTracePayload=this.generateTracePayload.bind(this),this.shouldGenerateTrace=this.shouldGenerateTrace.bind(this)}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var r=(0,t.DL)(this.agentIdentifier);if(!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof c._A?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,D.P)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var r=!1,n={};if((0,t.Mt)(this.agentIdentifier,"distributed_tracing")&&(n=(0,t.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)r=!0;else if(n.allowed_origins instanceof Array)for(var i=0;i 2&&void 0!==arguments[2])||arguments[2];super(r,n,Z.t,i),(0,t.OP)(r).xhrWrappable&&(this.dt=new W(r),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee),(0,k.u5)(this.ee),(0,k.Kf)(this.ee),function(r,n,i,o){function a(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,O.m$)(!1)),c.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,O.m$)(!1))}function s(e){this.params={method:e[0]},T(this,e[1]),this.metrics={}}function u(e,n){var i=(0,t.DL)(r);i.xpid&&this.sameOrigin&&n.setRequestHeader("X-NewRelic-ID",i.xpid);var a=o.generateTracePayload(this.parsedOrigin);if(a){var s=!1;a.newrelicHeader&&(n.setRequestHeader("newrelic",a.newrelicHeader),s=!0),a.traceContextParentHeader&&(n.setRequestHeader("traceparent",a.traceContextParentHeader),a.traceContextStateHeader&&n.setRequestHeader("tracestate",a.traceContextStateHeader),s=!0),s&&(this.dt=a)}}function d(e,t){var r=this.metrics,i=e[0],o=this;if(r&&i){var a=V(i);a&&(r.txSize=a)}this.startTime=(0,p.z)(),this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof t.onload)&&"function"==typeof o.end)&&o.end(t)}catch(e){try{n.emit("internal-error",[e])}catch(e){}}};for(var s=0;s 1?e[1]=i:e.push(i)}else e[0]&&e[0].headers&&s(e[0].headers,n)&&(this.dt=n);function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,p.z)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof Y?r=i.url:c._A?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),T(this,r);var o=(""+(i&&i instanceof Y&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.txSize=V(n.body)||0}function A(t,r){var n;this.endTime=(0,p.z)(),this.params||(this.params={}),this.params.status=r?r.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var o={txSize:this.txSize,rxSize:n,duration:(0,p.z)()-this.startTime};i("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,e.D.ajax)}function E(t){var r=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;o 2&&void 0!==arguments[2])||arguments[2];super(e,t,we.t,r),this.importAggregator()}}new class{constructor(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);c._A?(this.agentIdentifier=t,this.sharedAggregator=new y({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(m),Object.assign(this,(0,a.j)(this.agentIdentifier,e,e.loaderType||"agent")),this.start()):(0,l.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,t.C5)(this.agentIdentifier),init:(0,t.P_)(this.agentIdentifier),loader_config:(0,t.DL)(this.agentIdentifier),runtime:(0,t.OP)(this.agentIdentifier)}}start(){const t="features";try{const r=n(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((t,r)=>e.p[t.featureName]-e.p[r.featureName])),i.forEach((t=>{if(r[t.featureName]||t.featureName===e.D.pageViewEvent){const n=function(t){switch(t){case e.D.ajax:return[e.D.jserrors];case e.D.sessionTrace:return[e.D.ajax,e.D.pageViewEvent];case e.D.sessionReplay:return[e.D.sessionTrace];case e.D.pageViewTiming:return[e.D.pageViewEvent];default:return[]}}(t.featureName);n.every((e=>r[e]))||(0,l.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,D.P)(n),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,T.Qy)(this.agentIdentifier,this.features,t)}catch(e){(0,l.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",e);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,T.fP)();return delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,r.ee?.abort(),delete r.ee?.get(this.agentIdentifier),!1}}}({features:[J,m,S,class extends h{static featureName=oe;constructor(t,r){if(super(t,r,oe,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;const n=this.ee;let i;(0,k.QU)(n),this.eventsEE=(0,k.em)(n),this.eventsEE.on(se,(function(e,t){this.bstStart=(0,p.z)()})),this.eventsEE.on(ae,(function(t,r){(0,s.p)("bst",[t[0],r,this.bstStart,(0,p.z)()],void 0,e.D.sessionTrace,n)})),n.on(ce+ne,(function(e){this.time=(0,p.z)(),this.startPath=location.pathname+location.hash})),n.on(ce+ie,(function(t){(0,s.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,e.D.sessionTrace,n)}));try{i=new PerformanceObserver((t=>{const r=t.getEntries();(0,s.p)(te,[r],void 0,e.D.sessionTrace,n)})),i.observe({type:re,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},C,xe,B,class extends h{static featureName=de;constructor(e,r){if(super(e,r,de,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;if(!(0,t.OP)(e).xhrWrappable)return;try{this.removeOnAbort=new AbortController}catch(e){}let n,i=0;const o=this.ee.get("tracer"),a=(0,k._L)(this.ee),s=(0,k.Lg)(this.ee),u=(0,k.BV)(this.ee),d=(0,k.Kf)(this.ee),f=this.ee.get("events"),l=(0,k.u5)(this.ee),h=(0,k.QU)(this.ee),g=(0,k.Gm)(this.ee);function m(e,t){h.emit("newURL",[""+window.location,t])}function v(){i++,n=window.location.hash,this[ve]=(0,p.z)()}function b(){i--,window.location.hash!==n&&m(0,!0);var e=(0,p.z)();this[pe]=~~this[pe]+e-this[ve],this[ye]=e}function y(e,t){e.on(t,(function(){this[t]=(0,p.z)()}))}this.ee.on(ve,v),s.on(be,v),a.on(be,v),this.ee.on(ye,b),s.on(ge,b),a.on(ge,b),this.ee.buffer([ve,ye,"xhr-resolved"],this.featureName),f.buffer([ve],this.featureName),u.buffer(["setTimeout"+le,"clearTimeout"+fe,ve],this.featureName),d.buffer([ve,"new-xhr","send-xhr"+fe],this.featureName),l.buffer([me+fe,me+"-done",me+he+fe,me+he+le],this.featureName),h.buffer(["newURL"],this.featureName),g.buffer([ve],this.featureName),s.buffer(["propagate",be,ge,"executor-err","resolve"+fe],this.featureName),o.buffer([ve,"no-"+ve],this.featureName),a.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),y(l,me+fe),y(l,me+"-done"),y(a,"new-jsonp"),y(a,"jsonp-end"),y(a,"cb-start"),h.on("pushState-end",m),h.on("replaceState-end",m),window.addEventListener("hashchange",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){m(0,i>1)}),(0,O.m$)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}],loaderType:"spa"})})(),window.NRBA=o})(); window.jQuery || document.write(' ') CKEDITOR_BASEPATH='https://f1000research.com/js/vendor/ckeditor/' window.reactTheme = 'research'; window.MathJax = { CommonHTML: { linebreaks: { automatic: true } }, 'HTML-CSS': { linebreaks: { automatic: true } }, SVG: { linebreaks: { automatic: true } }, AuthorInit: function() { MathJax.Hub.Register.MessageHook('End Process', function () { let timeout = false; // holder for timeout id const delay = 250; // delay after event is "complete" to run callback const reflowMath = function() { const dispFormulas = document.querySelectorAll('.disp-formula.panel'); if (!dispFormulas) { return; } for (const dispFormula of dispFormulas) { const child = dispFormula.querySelector('.MathJax_Preview').nextSibling.firstChild; const isMultiline = MathJax.Hub.getAllJax(dispFormula)[0].root.isMultiline; if (dispFormula.offsetWidth < child.offsetWidth || isMultiline) { MathJax.Hub.Queue(['Rerender', MathJax.Hub, dispFormula]); } } }; window.addEventListener('resize', function() { clearTimeout(timeout); // clear the timeout timeout = setTimeout(reflowMath, delay); // start timing for event "completion" }); }); }, }; if (window.location.hash == '#_=_'){ window.location = window.location.href.split('#')[0] } !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function() {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)} ;if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1641728616063202'); fbq('track', "PixelInitialized", {}); (function(h,o,t,j,a,r){ h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)}; h._hjSettings={hjid:2318163,hjsv:6}; a=o.getElementsByTagName('head')[0]; r=o.createElement('script');r.async=1; r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv; a.appendChild(r); })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv='); search file_upload Submit your research search menu close search Browse Gateways & Collections How to Publish Submit your Research My Submissions Article Guidelines Article Guidelines (New Versions) Open Data, Software and Code Guidelines Open Data and Accessible Source Materials Guidelines (HSS) Open Data, Software and Code Guidelines (PSE) Prepublication Checks Production Process Posters and Slides Guidelines Document Guidelines Article Processing Charges Peer Review Finding Article Reviewers About How it Works For Reviewers Our Advisors Policies Glossary FAQs For Developers Newsroom Contact My Research Submissions Content and Tracking Alerts My Details Sign In file_upload Submit your research { "@context": "https://schema.org", "@type": "ScholarlyArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://f1000research.com/articles/13-1390" }, "headline": "Biological properties of Moringa oleifera: A systematic review of the last decade", "datePublished": "2024-11-19T16:01:47", "dateModified": "2025-01-30T16:24:34", "author": [ { "@type": "Person", "name": "Javier Andrés Soto" }, { "@type": "Person", "name": "Andrea Catalina Gómez" }, { "@type": "Person", "name": "Maryeli Vásquez" }, { "@type": "Person", "name": "Andrea Natalia Barreto" }, { "@type": "Person", "name": "Karen Shirley Molina" }, { "@type": "Person", "name": "C. A. Zuniga-Gonzalez" } ], "publisher": { "@type": "Organization", "name": "F1000Research", "logo": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 480, "width": 60 } }, "image": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 1200, "width": 150 }, "description": " Background The growing incidence of chronic diseases such as cancer and the emergence of drug-resistant microorganisms constitute one of the greatest health challenges of the 21st century. Therefore, it is critical to search for new therapeutic alternatives. Moringa oleifera is a plant well known for the properties of its phytocomponents and its role has been analyzed in a variety of fields, from medicine to biotechnology. Methods In this work, the biological activity of Moringa oleifera in human health was explored through a review of 129 original articles published between 2010 and 2021 related to antitumor activity and its potential uses against chronic and infectious diseases. Results Moringa oleifera extracts showed antioxidant, hypoglycemic, antihypertensive and cytoprotective properties at neuronal, hepatic, renal and cardiac levels. Besides, cytotoxic effects, apoptotic and antiploriferative activity against several cancer cell lines has been demonstrated. On the other hand, the antimicrobial potential of M. oleifera was also evidenced, especially against multidrug-resistant strains. Conclusions Hence, it is supported that there is a wide range of clinical entities in which Moringa oleifera exhibits significant biological activity that could contribute to counteracting metabolic, infectious and chronic diseases in a similar or improved way to the drugs traditionally used. " } { "@context": "http://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://f1000research.com/", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://f1000research.com/browse/articles", "name": "Browse" } }, { "@type": "ListItem", "position": "3", "item": { "@id": "https://f1000research.com/articles/13-1390", "name": "Biological properties of Moringa oleifera: A systematic review of..." } } ] } Home Browse Biological properties of Moringa oleifera: A systematic review of... ALL Metrics - Views Downloads Get PDF Get XML Cite How to cite this article Soto JA, Gómez AC, Vásquez M et al. Biological properties of Moringa oleifera : A systematic review of the last decade [version 2; peer review: 3 approved] . F1000Research 2025, 13 :1390 ( https://doi.org/10.12688/f1000research.157194.2 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. Close Copy Citation Details Export Export Citation Sciwheel EndNote Ref. Manager Bibtex ProCite Sente EXPORT Select a format first Track Share ▬ ✚ Systematic Review Revised Biological properties of Moringa oleifera : A systematic review of the last decade [version 2; peer review: 3 approved] Javier Andrés Soto https://orcid.org/0000-0002-4786-3431 1 , Andrea Catalina Gómez 1 , Maryeli Vásquez 1 , Andrea Natalia Barreto 1 , Karen Shirley Molina 1 , C. A. Zuniga-Gonzalez https://orcid.org/0000-0002-2545-8304 2 Javier Andrés Soto https://orcid.org/0000-0002-4786-3431 1 , Andrea Catalina Gómez 1 , [...] Maryeli Vásquez 1 , Andrea Natalia Barreto 1 , Karen Shirley Molina 1 , C. A. Zuniga-Gonzalez https://orcid.org/0000-0002-2545-8304 2 PUBLISHED 30 Jan 2025 Author details Author details 1 Facultad de Ciencias Médicas y de la Salud, Instituto de Investigación Masira, University of Santander, Bucaramanga, Santander, 540003, Colombia 2 Area of knowledge of Agrarian and Veterinary Sciences Research Centre, Bioeconomy and Climate Change Unit Research, National Autonomous University of Nicaragua, Leon, Leon, Leon, 21000, Nicaragua Javier Andrés Soto Roles: Conceptualization, Formal Analysis, Methodology, Supervision, Validation Andrea Catalina Gómez Roles: Conceptualization, Investigation Maryeli Vásquez Roles: Investigation Andrea Natalia Barreto Roles: Conceptualization, Investigation Karen Shirley Molina Roles: Conceptualization, Investigation C. A. Zuniga-Gonzalez Roles: Visualization, Writing – Original Draft Preparation, Writing – Review & Editing OPEN PEER REVIEW DETAILS REVIEWER STATUS Abstract Background The growing incidence of chronic diseases such as cancer and the emergence of drug-resistant microorganisms constitute one of the greatest health challenges of the 21st century. Therefore, it is critical to search for new therapeutic alternatives. Moringa oleifera is a plant well known for the properties of its phytocomponents and its role has been analyzed in a variety of fields, from medicine to biotechnology. Methods In this work, the biological activity of Moringa oleifera in human health was explored through a review of 129 original articles published between 2010 and 2021 related to antitumor activity and its potential uses against chronic and infectious diseases. Results Moringa oleifera extracts showed antioxidant, hypoglycemic, antihypertensive and cytoprotective properties at neuronal, hepatic, renal and cardiac levels. Besides, cytotoxic effects, apoptotic and antiploriferative activity against several cancer cell lines has been demonstrated. On the other hand, the antimicrobial potential of M. oleifera was also evidenced, especially against multidrug-resistant strains. Conclusions Hence, it is supported that there is a wide range of clinical entities in which Moringa oleifera exhibits significant biological activity that could contribute to counteracting metabolic, infectious and chronic diseases in a similar or improved way to the drugs traditionally used. READ ALL READ LESS Keywords Biological activity, cancer, chronic diseases, infectious diseases, Moringa oleifera, phytochemical components. Corresponding Author(s) Javier Andrés Soto ( [email protected] ) Close Corresponding author: Javier Andrés Soto Competing interests: No competing interests were disclosed. Grant information: The author(s) declared that no grants were involved in supporting this work. Copyright: © 2025 Soto JA et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. How to cite: Soto JA, Gómez AC, Vásquez M et al. Biological properties of Moringa oleifera : A systematic review of the last decade [version 2; peer review: 3 approved] . F1000Research 2025, 13 :1390 ( https://doi.org/10.12688/f1000research.157194.2 ) First published: 19 Nov 2024, 13 :1390 ( https://doi.org/10.12688/f1000research.157194.1 ) Latest published: 30 Jan 2025, 13 :1390 ( https://doi.org/10.12688/f1000research.157194.2 ) Revised Amendments from Version 1 This updated version of the article reviews the biological activities of Moringa oleifera , with a specific focus on its dual potential in addressing two critical global health challenges: cancer and antimicrobial resistance. This review integrates data from diverse fields, including medicine, biotechnology, and phytotherapy, providing a broader and more interdisciplinary perspective compared to prior works that focused on single aspects of Moringa oleifera. Additionally, this version highlights newly identified mechanisms and potential clinical applications that were not extensively discussed in previous reviews. The article has been revised to incorporate a more balanced discussion of the limitations of Moringa oleifera , including potential toxicity, variability in efficacy, and challenges in standardizing extracts. These aspects were added to the conclusion section to offer a more cautious and evidence-based perspective. Furthermore, all abbreviations have been reviewed for consistency, and any inconsistencies, such as the use of different terms for the same entity, have been resolved. The manuscript also features improvements in language fluency and coherence, as well as a more accurate citation and placement of figures and references. These revisions align the article with current research gaps and underscore the therapeutic potential of Moringa oleifera while addressing its limitations. This updated version of the article reviews the biological activities of Moringa oleifera , with a specific focus on its dual potential in addressing two critical global health challenges: cancer and antimicrobial resistance. This review integrates data from diverse fields, including medicine, biotechnology, and phytotherapy, providing a broader and more interdisciplinary perspective compared to prior works that focused on single aspects of Moringa oleifera. Additionally, this version highlights newly identified mechanisms and potential clinical applications that were not extensively discussed in previous reviews. The article has been revised to incorporate a more balanced discussion of the limitations of Moringa oleifera , including potential toxicity, variability in efficacy, and challenges in standardizing extracts. These aspects were added to the conclusion section to offer a more cautious and evidence-based perspective. Furthermore, all abbreviations have been reviewed for consistency, and any inconsistencies, such as the use of different terms for the same entity, have been resolved. The manuscript also features improvements in language fluency and coherence, as well as a more accurate citation and placement of figures and references. These revisions align the article with current research gaps and underscore the therapeutic potential of Moringa oleifera while addressing its limitations. See the authors' detailed response to the review by Micaela Carvajal Alcaraz See the authors' detailed response to the review by Francisco Osorio-Acosta See the authors' detailed response to the review by Pradeep Singh READ REVIEWER RESPONSES 1. Introduction Natural resources, such as plants, have been used since ancient times to treat various diseases with positive results. Recently, the use of medicinal plants has gained significant interest in low-and middle-income countries. Among them, Moringa oleifera has emerged as a plant with immense potential for health and industry due to the beneficial properties of its components. 1 Moringa oleifera (MO) is a globally distributed Indian native tree whose various parts, including bark, leaves, roots, seeds, pods, fruits, and flowers, are consumed as therapeutic alternative to treat a wide range of ailments. This plant, particularly its leaves, 2 is highly nutritious, containing significant amounts of vitamins (A, C and E). Vitamin A plays a key role in vision, immunity, cell growth, differentiation and reproduction while vitamins C and E protect against free radicals, acting as potentantioxidants. The leaves are also rich in essential amino acids and minerals such as iron, phosphorus, potassium and calcium. Calcium is particularly crucial for blood coagulation, maintaining the nervous system, and supporting bone and tooth health, as well as helping delay the onset of osteoporosis. Furthermore, MO contains a variety of bioactive compounds, including terpenoids, anthraquinones and glycosides. 1 – 3 In addition to its nutritional value, Moringa oleifera has a low fat content (4.03-9.51%) with polyunsaturated fatty acids predominating over saturated fats. This suggests a potential link to the prevention of coronary heart disease. 3 Moreover, MO is rich in fiber, contributing to the detoxification of the gastrointestinal tract. The plant’s presence of isothiocyanates also grants it antibacterial properties. 4 Several studies have highlighted MO as a valuable plant providing both nutritional and medicinal benefits. However, the majority of studies have focused on in vitro analyses, with limited in vivo evidence, partly due to concerns about its cytotoxicity. While Moringa oleifera shows significant therapeutic potential, a key gap remains in understanding its in vivo effects, particularly concerning the variability of its efficacy and potential toxicological risks. This review aims to consolidate the evidence on newly identified mechanisms of action, particularly its role in modulating specific molecular pathways related to cancer progression and bacterial resistance. 1 Recent research has emphasized the leaf as the part of the plant with the highest biological potential, containing an array of vitamins and amino acids. Additionally, it demonstrates significant water purification capacity and exceptional nutritional value. 4 Despite these benefits, studies, such as one by Sultana (2020), report discrepancies regarding the protein content in the leaves, suggesting that environmental factors may influence its composition. 3 This review specifically examines the dual therapeutic potential of Moringa oleifera in addressing two critical global health challenges: cancer and antimicrobial resistance. By integrating findings from diverse fields such as medicine, biotechnology, and phytotherapy, this work offers a broader perspective compared to prior reviews that often focus on single disciplines. The data analysis presented here reflects the most relevant findings and explores the plant’s potential for overcoming limitations of conventional therapies, such as side effects, low specificity, and limited efficacy. 1.1 Moringa oleifera Moringa oleifera is a tree belonging to the Moringaceae family, native to the sub-Himalayan area of India, Pakistan, Bangladesh and Afghanistan whose genus has 13 species distributed from tropical to subtropical regions. 5 MO is a plant widely studied worldwide for its components since these confer it particularities of interest in areas such as health, aesthetics, and nutrition, among others. The most studied part is its leaves since these have been attributed different biological properties including antimicrobial, hypotensive, antiulcer, hypocholesterolemic, antispasmodic, antioxidant, anti-inflammatory and antitumor agent potential. 6 In relation to its chemopreventive role, Sreelatha et al. 7 evaluated the antitumor effect of Moringa oleifera leaf alcoholic extract (rich in phenolic compounds, such as quercetin and kaempferol) on glandular cervical cancer cells, revealing a potential in the inhibition of cell viability through the induction of apoptosis and oxidative stress through the generation of reactive oxygen species (ROS) and an antiproliferative effect, thus revealing a promising outlook as an antitumor alternative. 7 MO is one of the most cultivated and important medicinal plants in India and is considered as a staple food in various parts of the world since its valuable nutritional potential 4 due to the high content of minerals and vitamins such as iron, potassium, copper, zinc, magnesium, manganese, vitamin C, vitamin E, beta-carotene, among others. Different studies have been described associated with the leaf, seed, fruit, bark and flower of Moringa oleifera in several types of cancer, which have revealed the biological antitumor activity both in vitro and in vivo. One of these works was performed by Hussein et al. 8 in which they determined the components of Moringa oleifera seed essential oil in vitro that act as antioxidants, and showed the cytotoxic potential over tumor cell lines like human breast adenocarcinoma (MCF-7), colon carcinoma (HCT-116), human hepatocarcinoma (HepG2) and HELA cells (8). 1.2 Phytochemical features This plant has been considered of great curative relevance in relation to the presence of significant phytochemicals 9 also known as secondary metabolites such as polyphenols, tannins, sterols, terpenoids, flavonoids, saponins, anthraquinones, alkaloids and some reducing sugars mentioned along with anticancer elements, including glucosinolates, isothiocyanates, glycoside compounds and glycerol-1-9-octadecanoate. 10 Phenolic acid derivatives are elements with similarity to flavonoids, which have been related to plant protection against UV rays and also with other defensive mechanisms. One type of phenolic acid, chlorogenic acids, are known for protecting against diseases caused by oxidative stress. 11 Some of the main flavonoids found by Sultana and Anwar (2008) present in Moringa oleifera leaves are myricycin, quercetin and kaempferol, at concentrations of 5.8, 0.207 and 7.57 mg/g, respectively. 12 Moreover, Vergara-Jiménez et al. 13 point out that quercetin is found in MO dried leaves in concentrations of 100 mg/100 g. This phytochemical acts as a strong antioxidant and exhibits hypolipidemic, hypotensive and antidiabetic potential, which has been demonstrated in vivo with rats suffering from metabolic syndrome and rabbits with hyperlipidemia ( Figure 1 ). 13 Figure 1. Chemical structures of the most significant secondary metabolites of Moringa oleifera . Concerning the biological activity of MO against microorganisms, Padla et al. 14 highlight that isothiocyanates isolated from Moringa oleifera seeds showed inhibitory activity at the lowest concentration of 1 mg/ml towards all Gram-positive bacteria tested ( Staphylococcus aureus , Staphylococcus epidermidis and Bacillus subtilis ) and against the dermatophyte fungi Epidermophyton floccosum and Trichophyton rubrum . 14 1.3 Traditional uses Several elements of this plant have been used traditionally in India as a preventive and treatment approach for pathologies such as asthma, gout, rheumatism, and infections. 15 Same scenario occurs in Africa where this MO is used to combat arthritis, joint pain, headaches, abdominal pain, otitis, and dental pain and it has also been used as a cardiac and circulatory stimulant, in individuals with asthenia, intestinal parasites, febrile periods, renal and hepatic complications, epilepsy, anemia, ulcers, delirium, and trauma caused by snakes. Moringa oleifera has been used to treat respiratory diseases such as influenza and asthma, and even SARS-CoV-2, which caused the last pandemic, 16 gastritis, headaches and flatulence 17 ; thus demonstrating its wide range of uses for a variety of clinical entities. It should be remembered that millions of people in the world do not have access to modern medicine, having to resort to the alternatives provided by ancestral medicine. 18 1.4 Antioxidant effect The relevance of the antioxidant activities of components that make up the Moringa oleifera plant, such as polyphenols, alkaloids, saponins, carotene, minerals, amino acids, and sterols, has been demonstrated. Such antioxidant features has been identified through several approaches, including colorimetric methods such as DPPHH (2,2-diphenyl-1-picrylhydrazyl), ABTS [2,2′-azino-bis-(3-ethylbenzothiazoline-6-sulfonic acid)], LPO (lipid peroxidation), FRAP (ferric reducing antioxidant power), among others, in order to obtain evidence related to the redox potential of the plant. 19 Polyphenols are phytochemicals found in large quantities especially in Moringa oleifera and are considered natural antioxidants. These are plant compounds that are attributed with the property of indirectly reducing oxidative damage in tissues by strengthening cells or eliminating free radicals. 20 It has been demonstrated that consumption of polyphenols protects against chronic pathologies related to oxidative stress, including cardiovascular diseases and cancer. 13 The presence of polyphenols in high concentrations in this plant leaves opens the door for their use in the aforementioned diseases. It is worth noting that to achieve the greater potential of antioxidants against damage caused by free radicals, the synergistic work of several antioxidants is necessary. A combination of effective antioxidants n the leaves of Moringa oleifera has been found 21 among then, polyphenols, mostly flavonoids (myricetin, quercetin, and kaempferol), together with phenolic acids (chlorogenic acid, caffeic acid, and gallic acid). 22 Moringa oleifera extracts exhibit strong antioxidant activity and radical scavenging in vivo , protecting animals against oxidative stress-induced diseases. Consumption of leaf and seed extracts has shown significant therapeutic properties against diabetes and hypertension due to the phyto-components, exhibiting mitochondrial redox potential, increasing heme oxygenase-1 and reducing reactive oxygen species (ROS) induction as well as lipid peroxidation, thus conferring protective effects against negative effects associated with obesity. 23 , 24 It is even suggested that its antioxidant capacity is so promising that the role of Moringa oleífera derivatives should be explored in the treatment of wastewater and as a future source of important nutraceuticals. 21 1.5 Anticancer activity The potential of Moringa oleifera as an anticancer agent has been elucidated through the role of ethanolic extracts obtained from the leaves and bark which have effectively inhibited the growth of cancer cells in breast, pancreas, and colorectal tissue. It is believed that the plant’s antitumor capacity is due to the presence of isothiocyanates, glucosinolates, glycosylated compounds, and glycerol 1-9-octadecanoate. 25 It has also been proved that Moringa oleifera pods act as a chemo preventive agents in vivo . This protective effect has also been identified by Shaban et al., 26 who observed an in-crease in antioxidant levels and a reduction in the formation of free radicals against several cancer cell lines (lung, liver, colon, and neuroblastoma) treated with the plant. 26 Regarding the extract of Moringa oleifera seed, this has shown specific growth inhibitory effects reflected in a 95% inhibitory activity on neuroblastoma cell line. 27 In some cases, tumors treated with methanol extracts from fruits and leaves have grown slowly, indicating effective cell degradation. Likewise, it has been found that the extract is more effective in terms of volume, since at a concentration of 500 mg/kg, the doubling time and growth delay indicate tumor-suppressing properties. 27 2. Methods This compilation is of a qualitative, descriptive and documentary nature and its development required the collection of original scientific articles obtained from databases such as PubMed, ScienceDirect, EBSCO Host, Scopus, and Google Scholar. The number of records identified through the database search was 2700 publications initially. Subsequently, these raw results were processed using filters such as keywords including Moringa oleifera , chronic diseases, infectious diseases, biological activity, human cancer, antitumor biological activity, in vivo and in vitro activity and anticancer properties, aiming to identify and select relevant information for the analysis of biological activity against human diseases, thus reducing the number of potential publications to 410. From the articles found in the above-mentioned databases, an exclusion and inclusion process was carried out. Once the data was obtained, this information was housed in a categorization matrix that specified different items such as access link, title, authors, journal, year, methodology, results, conclusions, and discussions aiming to synthesize the information and making it more accessible for a selective and exclusive analysis. This screening and analysis process allowed to obtain a total of 112 definitive publications. It is important to highlight that not only the articles described in the results section were used, this means that there is a greater number of articles mentioned and analyzed since other bibliographic sources were added in the rest of the body of the document. A systematic literature review was conducted using academic databases such as PubMed, Scopus, and Google Scholar. Original articles published between 2010 and 2021 that investigated the biological activity of Moringa oleifera in relation to its antitumor activity and potential uses against chronic and infectious diseases were included. 2.1 Inclusion and exclusion criteria Inclusion criteria included studies that: a) Addressed the biological activity of Moringa oleifera. b) Presented empirical results regarding its antitumor properties or effects on chronic and infectious diseases. c) Were original articles peer-reviewed. d) Exclusion criteria comprised reviews, editorials, and articles not published in English or Spanish. 2.2 Review process A search was performed using keywords such as “ Moringa oleifera ,” “antitumor,” “chronic diseases,” and “infectious diseases.” Following the initial search, titles and abstracts were screened to filter relevant articles. A full reading of the selected articles was then conducted to extract data on biological activity and proposed mechanisms. 2.3 Data analysis The findings from the selected articles were synthesized, highlighting the most relevant biological properties and methodologies employed in each study. A descriptive approach was used to summarize results and discuss the implications of the findings for human health. 3. Results and discussion 3.1 Chronic, infectious diseases and cancer Chronic diseases are characterized by a long course and slow progression, and include cardiovascular diseases, cancer, chronic kidney and liver diseases, rheumatic disease, and diabetes. According to the World Health Organization (WHO), chronic diseases are the leading cause of mortality worldwide, causing approximately 41 million deaths each year, equivalent to 71% of deaths globally. 28 These pathologies can be prevented by modifying common behavioral risk factors, such as smoking, alcohol consumption, unhealthy diet, and physical inactivity, which contribute to the development of metabolic changes that usually manifest themselves as hypertension, obesity, hyperglycemia, and hyperlipidemia. 29 Specific genetic events and external agents such as physical carcinogens such as ultraviolet (UV) and ionizing radiation, chemical carcinogens such as asbestos, aflatoxins, arsenic, and biological carcinogens (e.g. Helicobacter pylori , viruses, and parasites) increase disease morbidity. 30 However, cardiovascular diseases are positioned before cancer, as they are the leading cause of death among chronic diseases (approximately 18 million deaths per year), followed by cancer (9 million deaths per year) and diabetes (1.6 million deaths per year). 28 These three pathologies are responsible for more than 80% of premature deaths, that is, fatal events occurring between the ages of 30-69 years. 29 Concerning infectious diseases, which are basically foodborne illnesses (FBIs), sexually transmitted infections (STIs) such as HIV/AIDS, acute respiratory infections (ARIs) including the common flu and the current novel coronavirus (COVID-19), and other parasitic and bacterial diseases; a global increase in drug resistance rates has been identified, indicating a loss of effectiveness in usual treatments. Regarding antiviral resistance, there is an increasing concern, mainly for immunocompromised patients, as well as for the emergence of drug-resistant parasites, which constitute one of the greatest threats to malaria control. In the case of drug-resistant fungal infections, the therapeutic situation is already difficult se because patients currently experience treatment problems, such as toxicity, especially in individuals with other underlying infections. 31 Some infections can be prevented by vaccination; however, the increasing resistance to antimicrobials (antibiotic, antiviral, antifungal, and antiparasitic) due to their inappropriate and excessive use has led to some of these diseases becoming a global public health problem owing to an increase in morbidity and mortality rates, long hospital stays, and high healthcare costs. 31 Therefore, considering what has already been described, a viable therapeutic alternative is found in natural and complementary medicine based on the use of plant material, its extracts, and derivatives. In recent decades, medicinal plants have become a trend in developing countries, with Moringa oleifera as a promising plant because several studies have demonstrated its therapeutic and pharmacological properties, including neuroprotective, antimicrobial, antiasthmatic, antimalarial, cardioprotective, antidiabetic, antiobesity , hepatoprotective, and anticancer effects. 1 Chronic diseases have had a significant impact worldwide due to their high mortality rates and the fact that their related therapies often have side effects on patients. Based on this, there is a need to explore other therapeutic alternatives, such as natural treatments, including the use of Moringa oleifera , which has shown positive effects regarding the potential treatment of such diseases over time, as revealed in this study. In the following sections, several in vitro and in vivo studies conducted between 2010 and 2021 on the use of Moringa oleifera in the aforementioned clinical events are described. 3.2 Biological activity of Moringa oleifera in chronic diseases Cardiovascular diseases are chronic diseases and are of great interest because they rank first as the cause of death worldwide. However, in chronic diseases, another clinical entity attracts the attention of the medical community because of the rapid increase in incidence rates and high associated morbidity. According to data from the Diabetes Atlas, 463 million adults currently live with this disease, and the global projection of cases for 2025 is 438 million, but this prediction has already been exceeded by 25 million cases. 32 Making the scenario more complex, this pathology is not diagnosed or is misdiagnosed in low-income countries, increasing the risk of serious complications and mortality. Additionally, the lack of availability of diabetes medications is a challenge. The projections for this disease are not only gloomy regarding the well-being of individuals but also in terms of fiscal detriment to global health systems, as expenses related to the disease are estimated to reach over one billion dollars by 2045. 33 3.2.1 Therapeutic properties for chronic diseases In India, the native country of the plant, Aju et al. 34 evaluated the protective role of the methanolic extract of Moringa oleifera leaves (MOME) in the hearts of diabetic rats and demonstrated that treatment with MOME at a dose of 300 mg/kg/day significantly reduced hyperglycemia and oxidative stress in the hearts of the animals. 34 The potential antidiabetic and antioxidant properties of MOME were attributed to the presence of various biologically active compounds, such as heptadecanoic acid, hexadecanoic acid, DL-alpha-tocopherol, 11-14-17-eicosatrienoic acid, and 9-12-15-octadecatrienal, which have been previously associated with the antiarthritic and anticoronary activities of the plant. 34 In line with the antidiabetic study, Khan et al. 35 used the aqueous extract of Moringa oleifera leaf (AEMOL) at a dose of 100 mg/kg in streptozotocin-induced diabetic rats to determine the hypoglycemic potential to assess the enzymatic activity, seeking to identify the antioxidant capacity due to the presence of compounds such as phenols. 35 However, the evaluation of inhibitory activities and potential radical scavengers of two promising plants ( M. oleifera and T. occidentalis ) on the enzymes highlighted in diabetes mellitus revealed enzyme inhibition, 36 with Moringa oleifera being the major contributor to this event in a dose-dependent manner. Another relevant finding of this study was related to the identification of a greater number of phytoconstituents in Moringa oleifera than in Telfairia occidentalis. 36 Concerning the antidiabetic role of Moringa oleifera leaf powder, the chemical composition of this substance has been evaluated with regard to the inhibition of α-amylase enzyme, testing the inclusion of 20 g of Moringa oleifera leaf powder in natural foods and studying in diabetic and healthy patients. From these analyses, it was found that Moringa oleifera leaf powder contains a high amount of protein, fiber, and trace elements, in addition to known polyphenols. 37 Approaches focused on demonstrating an association between the potential of leaf extracts and therapy for vascular diseases have evaluated the antihypertensive mechanisms of the aqueous extract of Moringa oleifera leaves (AEMOL). Aekthammarat et al. 38 concluded that AEMOL induces the synthesis of Nitric Oxide (NO) in endothelial cells, thus reducing peripheral vascular tone and blood pressure (BP), a dependent event on soluble guanylate cyclase (sGC). This induces vasorelaxation through the activation of the eNOS-NO-sGC pathway, allowing us to understand the pharmacological properties of AEMOL against arterial hypertension. 38 The seeds of Moringa oleifera seeds have also shown potential for exhibiting antidiabetic effects. Al-Malki and Rabey 39 tested low doses of Moringa oleifera seed powder (50 and 100 mg/kg) in rats with induced diabetes. Using various methodological approaches, such as biochemical, immunological, physiological, and histological analyses they observed that low doses decreased lipid peroxidation to a greater extent than the 100 mg/kg concentrations. They also found that antioxidant enzyme levels increased in the treated groups. Specifically, regarding glycosylated hemoglobin, rats treated with M. oleifera showed significantly reduced values, although the most drastic change was associated with the dose of 100 mg/kg. 39 The methanolic extract of Moringa oleifera seeds (MEMOS) has been evaluated for its ability to alter serum lipid profiles. An example of this is the assessment carried out by Ajayi et al., 40 where weight gain was observed in untreated animals compared to those treated with this extract. It was also noted that there was a decrease in total cholesterol (<0.05) in experimental animals administered MEMOS at 100 mg/kg, but this effect was not significant at 200 mg/kg. Regarding high-density lipoprotein (HDL), it was found that in groups treated with both concentrations of MEMOS, this parameter increased, but this increase was more significant at 200 mg/kg. 40 Table 1 shows some in vivo and in vitro concerning the potential of extracts obtained from different parts of the plant to counteract some chronic diseases. Table 1. Potential uses of Moringa oleifera in chronic diseases. Plant part Extract fraction Disease Effects Mechanisms References Leaf Methanolic, aqueous, powder, ethyl acetate Diabetes mellitus Hypoglycemic Inhibition of α-amylase and α-glucosidase enzymes. 34 – 37 , 39 , 41 – 43 Aerial parts (stem, leaf and pods) Ethanólic HbA1c decrease Seed Powder Increase of plasmatic insulin Leaf Aqueous and methanolic Cardiovascular diseases Cardioprotector Decrease lipid peroxidation products 38 , 44 , 45 Antihypertensive Increase cardiac antioxidant enzymes Seed Dust Decreased heart rate Activation of the eNOS-NO-sGC pathway Leaf Ethyl acetate, hydroalcoholic, ethanolic Renal insufficiency Nefroprotective Antioxidant 46 – 48 Bark Methanolic Antiinflamatory Seed Powder Normalizes renal function markers Leaf Powder, methanolic Obesity BMI decrease Regulation of the expression of genes involved in the regulation of body weight (leptin, adipo-nectin and resistin). 40 , 49 – 51 Bark Aqueous Decrease in total cholesterol, triglycerides and LDL-C and increase in HDL-C. Leaf Ethanolic Arthritis Antiarthritic Inhibition of arthritic edema 52 Leaf Ethanolic, Methanolic Neurodegenerative diseases Neuroprotective Decreased activity of apoptotic brain markers 53 – 55 Leaf Aerial parts (stem, leaf and pods) Powder, hydroalcoholic, ethanol, ethanolic Ethanolic Liver damage Hepatoprotective To prevent the toxic effect of arsenic in humans and the treatment of other chronic pathologies derived from arsenic. Antioxidant 46 , 56 – 58 3.3 Biological activity of Moringa oleifera on cancer The International Agency for Research on Cancer (IARC) states that in 2020 there were 19.3 million new cases of cancer and nearly 10 million deaths. 59 According to the Global Cancer Observatory (GCO), lung cancer is the most commonly diagnosed cancer in men (14.3%), followed by prostate cancer (14.1%) and colorectal cancer (10.6%). In women, the most common type of neoplasia and the one with the highest mortality rate was breast cancer (24.5%), followed by colorectal cancer (10.6%) and lung cancer (8.4%). 59 It is predicted that by 2030, there will be a 32% increase in the number of people diagnosed with cancer in the Americas. 60 Currently, the main therapies used against cancer in medical oncology are surgery, hormonal therapy, radiation, immunotherapy, and chemotherapy. Despite their widespread use, these approaches have adverse effects because they affect cells that are in constant division, such as the bone marrow, lining of the mouth and intestines, and hair follicles. The type of side effect depends on the type of medication used, amount administered, and treatment time. The use of conventional approaches such as chemotherapy has resulted in very low survival rates for patients with advanced-stage cancer. 61 3.3.1 In vitro antitumor evidence With the aim of elucidating the potential antitumor capacity of various extracts from Moringa oleifera , Cuellar et al . 62 conducted a study related to the effect of hydrolyzed extracts from the plant leaves on human colon cancer cells, HT-29 and HCT116, showing similar cytotoxic activity in both cell lines compared to untreated cells. 62 According to the types of extracts evaluated in the study, it was observed that the aqueous extract, the methanolic extract, and the glucosinolate-rich hydrolysate showed the highest cytotoxic effect on the HCT116 human colon cancer cell line at concentrations of 20.1%, 21%, and 21.5%, respectively, unlike the HT-29 human colon cancer cell line, in which only the aqueous and methanolic extracts showed higher cytotoxicity at concentrations of 19.8% and 22%, respectively. 62 To determine the possible mechanism responsible for the observed tumor cytotoxicity associated with this plant, the apoptotic and antiproliferative activity of the aqueous extract of Moringa oleifera leaf in human melanoma cell lines A375, A2058, and normal human fibroblasts was assessed. This biological activity was evaluated through the implementation of the WST-1 cell proliferation assay and the Annexin V-associated apoptosis assay, showing that the aqueous extract causes growth inhibition due to apoptosis events in the target lines. 63 However, there was little effect on the growth of normal human fibroblasts, thus revealing the specificity of this compound. 63 Therefore, the aqueous extract of Moringa oleifera can be considered an alternative therapy for the treatment of skin cancer, while keeping in mind the importance of continuing in vitro and in vivo studies that provide scientific information about the biological activity of this plant. Several approaches associated with the study of the antitumor and chemopreventive capacities of Moringa oleifera are summarized in Table 2 . Table 2. In vitro potential uses of Moringa oleifera regarding cancer. Plant part Biological activity Disease Effect References Leaf Whole plant Flowers Citotoxic activity Colorectal cancer, breast cancer,laryngeal cancer, cervical cancer, lung cancer, prostate cancer and leukemia The presence of quinic acid, octadecanoic acid, palmitic acid (hexadecanoic acid), alpha-tocopherol (vitamin E), and β-sitosterol induce toxicity. 62 , 66 – 75 Leaf Seed Root Apoptotic activity Skin cancer, Cervical cancer Cellular morphological alterations due to membrane shrinkage, nuclear contraction, condensation, and fragmentation of DNA. 7 , 63 , 76 – 82 Fruit Leaf Seed Cell viability Liver cancer, lung cancer, breast cancer The extract from different parts of Moringa oleifera shows great variability with respect to cancer cells, since the toxic effect of the extract is lower in normal cells than in cancer cells. 64 , 83 , 84 Leaf Seed Antiproliferative activity Lung cancer, prostate cancer, liver cancer, and squamous cell carcinoma The leaves and seeds of Moringa oleifera possess antiproliferative properties as demonstrated by an increase in oxidative stress that leads to apoptosis of tumor cells. 85 – 87 Leaf Anticancer activity Epidermoid cancer Extracts from Moringa oleifera (n-hexane, chloroform, ethyl acetate, and methanol) were studied. The methanolic extract showed the highest effectiveness in inhibiting cancer cells. 88 Leaf, bark Cell survival Ileocecal cancer and breast cancer Leaf extracts mainly consist of thiocyanates, hydrocarbons, and fatty acids, while bark extract is primarily composed of hydrocarbons, phenols, phthalates, carboxylic acids, and long-chain fatty acids, which can decrease cell survival. 65 Leaf and seed Antioxidant activity Breast cancer, colon cancer, liver cancer, leukemia and adenocarcinoma. Moringa's ethanol extract exhibits antioxidant activity, which is characteristic of its high concentrations of phenols and flavonoids. 89 , 90 Attempting to explore the potential of the Moringa plant not only regarding its leaves but also other elements, Adebayo et al. 64 evaluated the cytotoxic activity and inhibition of cell proliferation of crude extracts and fractions of MO seeds on breast adenocarcinoma cells (MCF7) and normal breast cells (MCF10A) and found an insignificant effect of the crude ethanol extract on the proliferation of MCF7 cells. 64 In contrast, the dichloromethane fraction of the crude ethanol extract, the hexane fraction of Moringa oleifera seed, and the crude aqueous extract inhibited proliferation. 64 The observed cell inhibition effects in this study were most likely due to the presence of phenols. The hexane fraction of the ethanol extract exhibited the best effect, as it showed antitumor activity against MCF7 cells, while having limited cytotoxicity against normal breast cells. 64 To determine the properties of Moringa oleifera in other tumor cell lines, a study targeting breast cancer cells (MDA-MB-231) and colorectal cancer cells (HCT-8) was conducted with the aim of identifying phenotypic changes, effects on cell viability, apoptosis, and alteration of the cell cycle. The results did not show a significant decrease in cell populations when exposed to different parts of the plant; however, the seed extract decreased cell motility and colony formation in both cell lines, despite not directly affecting their survival. 65 Regarding to the whole plant studies Diab et al . 91 conducted a research aimed to explore the in vitro antiproliferative potential of extracts from the entire Moringa oleifera plant on cell lines of lung cancer (A549), prostate (PC-3), breast (T47D and MCF-7), colon (HCT-16, Colo-205), and leukemia (THP-1, HL-60) using two methods: cytotoxicity assay and MTT assay. The results showed in vitro cytotoxic activity of the plant extract actively inhibiting the growth of cancer cells in the cell lines A549, PC3, MCF-7, and HCT 92 ; however, it showed a moderate effect on T47D, Colo-205, THP-1, HL-60, and K562 cells. 91 3.3.2 In vivo antitumor evidence In an effort to identify the potential therapeutic role of Moringa oleifera in preclinical trials, Barhoi et al published in 2021 the results of a study evaluating the cytotoxic activity of this plant in BALB/c mice with mammary adenocarcinoma. The mice were administered aqueous leaf extract for a week, and after follow-up, a reduction in tumor weight and volume was observed with increased survival of the mice, without significant alterations in the liver, kidney, or hematological parameters after the treatment. In parallel, in vitro evaluations were carried out, showing the dose-and time-dependent cytotoxic activity of the plant in two cell lines: HEp-2 human laryngeal carcinoma cells and EAC (Ehrlich Ascites Carcinoma) mouse mammary adenocarcinoma cells. Regarding the mechanisms involved in the observed cytotoxic effects, flow cytometry analysis confirmed the significant induction of tumor cell apoptosis by changing the mitochondrial membrane potential in the EAC cell line. 66 Another in vivo model considered the use of Sprague Dawley rats in which breast cancer was induced through treatment with 7,12-dimethylbenz(a) anthracene (DMBA), in order to analyze whether the combination of ethanolic extract of Moringa leaves and ethanolic extract of papaya leaves (Carica papaya L) 93 could delay the appearance of tumor tissue. The results showed that there were different changes in body weight among the groups of rats for 12 weeks, and the appearance of tumor tissue was detected in the 7th week in the DMBA comparison group, while in the positive control group and the combined extract group of Moringa oleifera and Carica papaya leaves, the solid period began to be detected in the tenth week. 93 According to histopathological tests, the growth of tumor tissue was found in all test animals, concluding that the combination of ethanolic extract of Moringa and Carica leaves at a dose of 150 mg/kg delayed the formation of cancerous tissue 93 ; therefore, they can be considered as chemopreventive agents. Similarly, Sadek et al. evaluated in vivo the chemoprophylactic efficacy of Moringa oleifera leaf ethanolic extract against hepatocellular carcinoma in male Wistar rats (40 male Wistar rats). 94 After determining the appearance and histological changes in the liver, they found that rats treated with Moringa oleifera leaf extract (MOLEE) showed a reduction in liver enlargement as well as in the bumps and morphological alterations that this organ had compared to the group of rats treated with diethylnitrosamine (DEN), indicating that MOLEE treatment generated a favorable change in hepatic architecture. 94 Continuing the trend regarding the study of ethanolic extracts, in 2020, the results of the effect of MOLEE on signaling pathways in response to DNA damage to protect hepatic tissue from apoptosis triggered by Cobalt Chloride (CoCl 2 ) in 40 male Sprague-Dawley rats were reported. The study showed that MOLEE reduced CoCl 2 -induced hepatic genotoxicity through the transcriptional induction of DNA damage repair genes, 95 thus suggesting that MOLEE is a promising candidate for the food, nutraceutical, and pharmaceutical industries. Several studies approaches associated with the study of the antitumor and chemopreventive capacity of Moringa oleifera are shown in Table 3 . Table 3. In vivo potential of Moringa oleifera regarding cancer. Plant parts Biological activity Potential Uses of Moringa oleifera Extract in Neoplasms Effect References Leaf Cell viability Lung and liver cancer Moringa oleifera leaf extract causes a decrease in liver cell viability (HepG2) after oral administration to mice. 86 Anticancer activity Dalton's lymphoma, epidermoid cancer, breast cancer The F1 fraction from Moringa oleifera leaves showed high anticancer activity when tested in in vivo mouse models. 66 , 73 , 88 Antiproliferative activity Breast cancer and liver cancer The ethanolic extract of Moringa leaves has an antiproliferative effect on human tumor lines, this effect is largely attributed to quercetin and moringinin. 96 Apoptosis Hepatocellular carcinoma, colorectal cancer Moringa oleifera leaf minimizes the protein expression of Bcl-2, Bcl-xl and B-arrestin-2. 46 , 92 , 94 Antioxidant activity Colorectal cancer Moringa's bioactive compounds, such as total dietary fiber and phenolic compounds, may have chemopreventive and antioxidant capacity. 97 Inhibition of tumor growth Pancreatic cancer, prostate cancer and breast cancer Moringa oleifera leaf extract decreased pancreatic cancer cell survival and significantly inhibited tumor growth. 72 , 93 , 98 Chemoprotective activity Hepatocellular carcinoma Moringa oleifera leaf extract (MOLEE) exhibits chemoprotective activity against diethylnitrosamine (DEN)-induced hepatocellular carcinoma. 94 Fruit Inhibition of tumor growth Apoptosis Skin cancer (Melanoma) and colon cancer Colon cancer Moringa oleifera fruits had effects in delaying the growth of skin tumors in mice. Moringa oleifera fruits (pods) possess suppressive capacity in carcinogenic processes and models in cancers such as colon cancer. 93 , 99 – 101 Moringa oleifera fruit or pod, boiled and known as BbMO showed effect as a chemotherapeutic agent against colon cancer by inducing the process of apoptosis. Seed Cytotoxicy Pulmonary mucoepidermoid carcinoma, adenocarcinoma of colon and liver Moringa oleifera aqueous seed extract shows no toxicity towards non-tumor cells in mice. Besides, it is an extract that has anti-inflammatory and moderate antitumor activity. 102 Anticancer activity Mama cancer It was observed that the mixture between leaf and seed residues in different proportions exhibits anticancer potential by interfering with the signal transduction cascade responsible for cancer proliferation and progression. 103 Flowers Antitumor activity Sarcoma The extract obtained from Moringa oleifera flowers showed antitumor effects at doses of 15 or 30 mg/kg, since there were reductions in tumor mass of about 97.9% compared to the negative control. 68 3.4 Biological activity of Moringa oleifera on infectious diseases Antimicrobial resistance crises must be urgently managed. The Global Action Plan on Antimicrobial Resistance acknowledges and addresses the variability of resources available to countries to fight antimicrobial resistance and the development of new antimicrobials by the pharmaceutical industry. 104 This has led to several studies in the last decade focusing on the biological activity of phytochemicals from Moringa oleifera against different infectious agents. 105 – 107 3.4.1 In vitro antimicrobial properties Within the wide range of characteristics exhibited by Moringa oleifera for the treatment of chronic diseases, the potential of extracts from different parts of the plant as antimicrobial agents has also been elucidated. Dzotam et al. 108 evaluated the antibacterial activity of the methanolic extract of M. oleifera leaves against sensitive and resistant strains of Escherichia coli, Enterobacter aerogenes, Klebsiella pneumoniae, Pseudomonas aeruginosa , and Providencia stuartii , as well as their synergistic effects with some antibiotics, finding growth inhibition in 13 (68.4%) of the 19 strains used. 108 Interestingly, it was also observed that the M. oleifera extract required one of the lowest minimum inhibitory concentrations compared to the other evaluated plants to counteract the growth of a multidrug-resistant strain. 108 Additionally, this extract showed synergistic effects with most of the antibiotics tested. 108 More recently and in line with Dzotam’s work, Umamaheswari et al . (2020) demonstrated the antimicrobial role of the plant, specifically against methicillin-resistant Staphylococcus aureus (MRSA) by evaluating the antimicrobial and antibiofilm potential of extracts from four plants, including Moringa oleifera. The ethanolic extract obtained from M. O leaves showed the lowest minimum inhibitory concentration (MIC) (250 μg/mL) and minimum bactericidal concentration (MBC) (500 μg/mL) among the evaluated plants. 109 The antimicrobial potential was attributed to terpenoids and flavonoids, which are the main groups of phytoconstituents with antimicrobial properties that are naturally present in plants. Furthermore, M. oleifera extracts showed–30-60% inhibition of biofilm formation, and other findings revealed that the extracts were not toxic and had minimal hemolytic activity. 109 Table 4 summarizes some in vitro experimental approaches focused on demonstrating the anti-infectious capacity of different parts of the Moringa oleifera plant. Table 4. In vitro potential of Moringa oleifera related with in infectious diseases. Plant part Extract fraction Potential use Pathogen References Leaf Solvents (acetone and methanol) Antimicrobial in co-infections associated with COVID-19 Pseudomonas aeruginosa, Escherichia coli, Moraxella catarrhalis, Serratia spp., Enterobacter spp., Staphylococcus aureus and Candida tropicalis 112 Methanolic and aqueous Antibacterial activity Gram-positive bacteria (Staphylococcus aureus and Streptococcus agalactiae) y gram-negative (Salmonella typhi and Shigella boydii) 113 Infusion S. aureus, K. pneumoniae, E. coli and P. aeruginosa 114 Methanolic Activity against gram-negative MDR bacteria Escherichia coli, Enterobacter aerogenes, Klebsiella pneumoniae, Pseudomonas aeruginosa and Providencia stuartii 108 Ethanolic Antimicrobial and anti-biofilm activity MRSA Methicillin-resistant Staphylococcus aureus 109 Anti-influenza activity Influenza A (H9) Virus 115 Anti-leishmanial properties Leishmania major 116 Methanolic, aqueous, and petroleum ether Inhibition of early events of the replication cycle HIV-1 lentiviral vector 110 Aqueous Antibiofilm and antiviral S. aureus , HSV-1 and HSV-2 117 Antimalaria Plasmodium falciparum 111 Ethanolic Aqueous Hidroalcoholic Antibacterial and antifungal activity Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Pseudomonas aeruginosa, Candida albicans Aspergillus niger and Rhizopus spp. 118 S. aureus, P. aeruginosa and E. coli, C. albicans and A. fumigatus 119 E. coli, K. pneumoniae, S. aureus and E. faecalis 120 , 121 Flower Methanolic Aqueous Isolated trypsin inhibitor protein: MoFTI Aqueous Antibacterial and antifungal activity Trypanocidal and immunomodulatory agent in Chagas disease Antibacterial activity Gram-positive bacteria (Monococcus luteus, Bacillus subtilis and Staphylococcus aureus) and gramnegativas (Salmonella paratyphi, Klebsiella pneumoniae and Pseudomonas aeruginosa ) Cándida albicans, Aspergillus fumigat us and Aspergillus niger Trypanosoma cruzi trypomastigotes Klebsiella pneumoniae and Staphylococcus aureus 122 – 125 Seed Methanolic Antiviral Influenza A virus 126 Anthelmintic activity Fasciola hepatica 127 Regarding the antiviral potential of the plant, the activity of different leaf extracts against the infectivity of the lentiviral vector HIV-1 has been studied. It has been found that all the tested extracts, including methanol (MM), aqueous (AM), and petroleum ether (EM) extracts were active against the vector, inhibiting early events of viral replication in HeLa cells in a concentration-dependent manner, with IC 50 values of 7.17 μg AM/mL, 7.72 μg MM/mL, and 7.59 μg EM/mL. 110 Another significant finding is related to the selectivity index of M. oleifera extracts, as they showed sufficiently high selectivity towards the lentivirus, indicating that the observed antiviral activities were not due to cytotoxicity, but rather to the presence of phytochemical components such as saponins, alkaloids, glycosides, tannins, carbohydrates, flavonoids, resins, acidic compounds, and proteins. 106 It has also been demonstrated that the leaves of this plant possess antiparasitic characteristics, as shown by Cudjoe et al., 111 who studied the short-term (72 h) and long-term (7 days) effects of aqueous leaf extracts from four selected plants collected from the western region of Ghana on the growth of NF54 (chloroquine-sensitive), CamWT_C580Y (artemisinin-sensitive), and IPC 4912 (artemisinin-resistant) strains of Plasmodium falciparum. Long-term treatment with derivatives of Moringa oleifera leaves at a dose of 100 μg/mL inhibited 80% of the development of asexual forms of the NF54 strain. 111 Such antiparasitic potential has been revealed not only in leaves but also in flowers. The anti- Trypanosoma cruzi activity and cytotoxicity in mammals of the aqueous extract of M. oleifera flowers, as well as the trypsin inhibitor protein isolated from this part, called MoFTI, have been evaluated. It was found that both the aqueous extract and MoFTI induced lysis of T. cruzi trypomastigotes with median lethal concentrations at 24 hours (CL 50 /24 h) of 54.18 ± 6.62 μg/mL and 41.20 ± 4.28 μg/mL, respectively. 124 Both products showed low toxicity to murine peritoneal macrophages and Vero cells, with cytotoxic concentrations greater than 400 μg/mL at 50% (CC 50 ). 124 This study postulated that the flavonoids present in the extract were responsible for the observed cytotoxicity, as suggested by other studies. The above is consistent with the findings from a study conducted by Nova et al . (2018) where treatment with MoFTI for 24 hours induced the lysis of T. cruzi tripomastigotes and did not affect the viability of human peripheral blood mononuclear cells (PBMCs). 123 The effects of MoFTI on the immune response of T. cruzi -infected human PBMCs showed that treatment with this compound at a dose of 87 μg/mL for 48 h stimulated the release of tumor necrosis factor (TNF) α and interleukin (IL) 10 by infected PBMCs, compared to those treated with the conventional drug for the acute phase of Chagas disease, benznidazole, which had no effect on cytokine modulation in infected and uninfected cells. 123 Thus, MoFTI is a potential trypanocidal and immunomodulatory agent in Chagas disease that can prevent its chronicity, so it should be taken into account and considered for future formulations developed by the pharmaceutical industry. Similarly, Moringa oleifera also exhibits antiviral effects in substances obtained from its seeds, as demonstrated in studies on its antiviral properties against influenza A virus (IAV) using methanol extract and apparent regulation of transcription factor EB (TFEB). Initially, Moringa oleifera showed low cytotoxicity towards RAW264.7, and protected infected cells from cytopathic effects (CPE), inhibiting cell lysis by up to 93.7%. 126 Furthermore, the hemagglutination assay was positive, indicating that the viral load in the groups treated with the extract was significantly reduced, particularly at concentrations of 5 and 10 μM. 126 Additionally, this extract suppressed autophagy in H1N1-infected cells, and it was established that this suppression was dependent on the decrease in TFEB levels in the nucleus of treated cells. Similar to the observations related to the MoFTI protein, the methanol extract of the seed also showed immunomodulatory properties, reflected in the reduction in TNF-α, IL-6, IL-1β, and IFN-β levels, suggesting that this extract may decrease the levels of inflammatory cytokines induced by H1N1 infection by inhibiting TFEB. 126 Regarding the potential antiparasitic activity of Moringa oleifera seeds, Kandil et al . 127 evaluated the in vitro and in vivo effects of the methanol extract of plant seeds on Fasciola hepatica as an alternative treatment. They found that complete inhibition of development and total death of immature Fasciola hepatica occurred within 48-72 hours after treatment at concentrations of 10, 25, and 50 mg/mL. 127 In addition, the results of in vivo assays showed a 20% decrease in the mean egg count per gram of feces two days after treatment in infected rabbits treated with a daily oral dose of 150 mg/kg of body weight of the extract for 3 days. On the last day of treatment, the egg count decreased by 68%, and from the seventh day onwards, no eggs were detected in the feces of the animals. 127 Thus, Moringa oleifera exhibited promising and potent activity against fascioliasis. 3.4.2 Therapeutic properties evaluated in silico. Approaches focused on demonstrating the antimicrobial characteristics of Moringa in preclinical assays are very scarce ( Table 5 ), but interestingly, studies based on computational tools were found, which were designed to elucidate the specific role of some molecules from M. oleifera extracts, all of which focused on the novel SARS-CoV-2 virus. These in silico studies evaluated active compounds from the plant to determine their inhibitory properties against the Mpro protease of SARS-CoV-2, a key protein involved in the pathogenesis of COVID-19, finding good docking with the protein, with kaempferol showing the highest inhibitory effect against SARS-CoV-2 Mpro. Quercetin, a compound present in moringa, showed significant assembly as well, indicating that the active phytoconstituents of this plant exhibit potential relative inhibitors against SARS-CoV-2 Mpro and pharmacological characteristics similar to hydroxychloroquine, making them possible antiviral candidates in the fight against COVID-19. 128 – 130 Other authors also mention that components such as niazirin, quercetin, moringin, 131 apigenin, and ellagic acid, 132 have an inhibitory role on the transmembrane serine protease 2 in SARS-CoV-2 infection and inhibition of two non-structural proteins 9/10 of SARS-CoV-2, respectively. Table 5 shows computational studies developed to demonstrate the anti-SARS-CoV-2 potential of Moringa oleifera. Table 5. In silico approaches of Moringa oleifera regarding infectious diseases. Plant part Phytocomponent with postive docking Potential use Phatogen References Whole plant Kaempferol and Quercetin Inhibition of the major protease of SARS-CoV-2 (Mpro) SARS-CoV-2 128 , 130 Niazirin, quercetin and moringin Inhibition of the transmembrane serine 2 protease in SARS-CoV-2 infection. 131 Apigenin and ellagic acid Inhibition of two nonstructural 9/10 proteins of SARS-CoV-2 133 3.5 Geographical data related to the study of Moringa oleifera in the last decade The compilation of scientific material developed here has allowed not only to understand the research trends of several authors exploring the potential of M. oleifera in different clinical conditions but also to elucidate the geographical landscape of the sources of such publications. As expected, the majority of publications originated from Asia, since the plant is native to these regions, with India and Egypt being the two main countries where research on the biological activity of M. oleifera in human health is conducted, particularly in chronic diseases ( Figure 2A ). Figure 2. Geographical origin of publications on the biological activity of Moringa oleifera . A) Studies on chronic diseases B) in vitro studies related to cancer C) in vivo studies related to cancer D) Studies in infectious diseases. It is noteworthy that Moringa oleifera leaf extract (MOLE) is known for its various cytoprotective properties owing to its high levels of antioxidants, polyphenols, and flavonoids, which improve organ function by acting as regulators of damage and oxidative stress. An example of this is a study carried out in Egypt by Abou-Zeid et al . 47 and Fathy et al ., 57 where the group of rats treated with MOLE showed less impact than the untreated group in terms of increased serum markers such as ALT, AST, urea, and creatinine, and decreased levels of albumin and total proteins, indicating protection against hepatic/renal toxicity. In Egypt, the neuroprotective activity of the ethanolic leaf extract described by Muhammed et al . 53 was reflected in a significant decrease in apoptotic-cerebral marker activity, such as caspase-3 and DNA fragmentation. 55 This resulted in nearly normal activity of the neurotransmitter acetylcholine as well as improved mitochondrial activity of NADH dehydrogenase and ATPase after treatment with the extract. These findings indicate that Moringa oleifera extract has an influence on the protection of mitochondrial function in neuronal cells, thus participating in the prevention of neurodegenerative diseases such as Parkinson’s disease caused by environmental factors. 55 India has the highest number of studies related to Moringa oleifera leaves. One of the research studies was proposed by Barhoi D, Upadhaya P, Barbhuiya S, Giri A, Giri S. 66 In 2021, this group developed an in vivo study on the anticancer potential of Moringa oleifera against ascetic and laryngeal cancers. The methodology involved two types of biological assays: the trypan blue dye exclusion assay and the MTT assay. The MTT assay revealed that treatment with Moringa oleifera induced dose- and time-dependent toxicity in both cancer types. This study highlights the potential of Moringa oleifera leaf treatment to induce apoptosis in cancer cells, indicating that this plant could be an excellent candidate for the development of new cancer therapies. In the context of in vitro antitumor screening, India again stands out as the country with the highest number of studies, contributing 26% of the overall production ( Figure 2B ). In 2010, Sreelatha reported the antiproliferative and apoptotic effects of the aqueous extract of Moringa oleifera leaves on a human tumor cell line (KB), using two types of biological assays, the cell proliferation assay and propidium iodide (PI) staining assay. The results showed that the aqueous extract significantly inhibited the proliferation of the studied tumor cell line and induced morphological changes (such as blistering of cell membrane) after 48 h of treatment, indicating apoptosis. 7 Moreover, cell membrane shrinkage and loss of contact with other cells were observed. Similarly, propidium iodide staining revealed nuclear contraction, condensation, and DNA fragmentation in the cells, 7 providing evidence of the significant biological effects of this extract, which could be prospectively used as a therapeutic and pharmacological product for treating certain neoplasms. Another interesting perspective in the present review involves the identification of regions from which in vivo research on the antitumor activity of Moringa oleifera has been conducted, which is not as abundant as in vitro approaches. In this regard, Egypt has led the production of studies in this area ( Figure 2C ), specifically focusing on leaves, contributing to 31% of the total related production. This indicates that Egypt has been actively involved in the research and evaluation of the anticancer potential of Moringa oleifera in vivo. Representative of one of these works are the observations of Khalil (2020), related with the evaluation of the effect of MOLEE on signaling pathways in response to DNA damage to protect hepatic tissue from apoptosis triggered by CoCl2 in Sprague-Dawley rats. This study demonstrated that MOLEE reduces genotoxicity induced by CoCl2, as evidenced by the expression of DNA repair genes. 9 Finally, concerning the biological activity of M. oleifera in infectious diseases, India was once again at the top of the list of articles in this field ( Figure 2D ). We highlight a study originating from that country concerning the use of extracts from certain plants to synthesize metallic nanoparticles to support the generation of new nanomaterials with more potent and/or novel biological activities. Das et al . 121 , 122 by performing green synthesis of copper 123 and bismuth 124 nanoparticles from hydroalcoholic leaf extracts revealed considerable antibacterial activity against Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus and Enterococcus faecalis , and relatively stronger antifungal activity against Aspergillus niger, Aspergillus flavus, Candida albicans and Candida glabrata , especially a pro-metabolic and usable inhibitory activity against Candida spp. 120 These findings suggest that the synthesized copper and bismuth nanoparticles may be promising therapeutic candidates for the treatment of various bacterial and fungal infections, such as candidiasis. Owing to their encapsulation, these nanoparticles can be used in direct medical applications as antimicrobial agents. An ecological advantage of green nanoparticle synthesis is the production of non-toxic materials and the reduction of waste products compared to incinerated nanoparticles synthesized by conventional chemical-thermal methods. 3.6 Plan parts mentioned in studies related with the biological activity of Moringa oleifera in chronic diseases, cancer and infectious diseases Although different parts of the plant have been studied under different conditions, in all experimental and preclinical approaches, the leaf is the most extensively studied raw material, mainly because of the relative ease of obtaining a viable product for testing. However, extracts from parts other than the leaf have also revealed effectiveness in the different research contexts in which they have been tested. Studies associated with chronic diseases and in vivo evaluations of cancer have led to the use of the leaves of this plant, with 73% and 71% of the investigations, respectively ( Figure 3A and 3C ), followed by in vitro assays on cancer and studies of antimicrobial potential, with 60% and 56%, respectively, that is, more than half of the investigations ( Figure 3B and 3D ). From this part of the plant, most scientific production has been generated, involving different types of extracts, among which aqueous, methanolic, and ethanolic extracts stand out. A small part of the work has studied the ethyl acetate extract; among them, the research carried out by Bamagous et al . 43 showed that this extract reverses diabetes markers such as serum levels of glucose and insulin, lipid profile, and liver damage, confirming the results of a histopathological study what was evaluated at the serum level. 43 Figure 3. Parts of Moringa oliefera used in studies related with the biological activity in A) Chronic diseases B) in vitro cancer studies C) in vivo cancer studies. D) Infectious diseases. With regard to the study of cancer, it has already been mentioned that most studies carried out to demonstrate the antitumor role of Moringa oleifera contemplate the leaf as a target element. One of these in vitro approaches was conducted by Khalafalla et al. 89 in Egypt in 2010, where different leaf extracts were evaluated to observe the effects of the treatment on the viability of leukemia and hepatocarcinoma tumor cells using the MTT assay. The results showed that the average viability of the treated tumor cells was 25% lower than that of the control cells (human lymphoid cell line), which was 94.6%. Likewise, with regard to the viability of the HpG2 tumor cell line (liver cancer), they observed a significant decrease with respect to treatment with ethanolic extract. 89 Studies on the leaves of this plant have been devoted not only to revealing the ability of these extracts to attack tumor cells but also to show their harmlessness to normal cells. Thus, Suphachai in Thailand conducted research on the in vitro antiproliferative activity of two types of Moringa oleifera leaf extracts (methanol and biomethanol) on breast cancer (MCF-7 cell line), liver cancer (HepG2), and human fibroblast cells. It was found that concentrations up to 400 μg/ml of the two extracts did not induce toxicity in normal cells. 90 Regarding the two extracts evaluated it was also observed that biomethanol was the one that presented high antioxidant activity and potent antiproliferative activity in cancer cells. 90 This study reinforces evidence that Moringa oleifera has great potential in the field of medicine in relation to cancer chemotherapy and chemoprevention. As observed in vitro, in vivo approaches also use leaves as their main raw material for research ( Figure 3C ). Among these, Cuellar et al. 97 focused on determining the physicochemical and nutraceutical properties of moringa leaves and their effects in a model of colorectal carcinogenesis in vivo. By testing Moringa oleifera leaf in male mice it could be evidenced that this extract decreased the activity of harmful fecal enzymes (β-glucosidase, β-glucuronidase, tryptophanase, and urease by up to 40%, 43%, 103%, and 266%, respectively), as well as tumor incidence in male CD1 mice. 96 These findings suggest that bioactive compounds in moringa, such as total dietary fiber and phenolic compounds, may have chemopreventive capacity. This is the first study on the suppressive effects of this plant leaf in an in vivo model of colorectal carcinogenesis. 105 The biological activity of the plant in infectious diseases, as in the other assays, is the most studied element ( Figure 3D ). Ashraf et al . 115 when comparing the cytotoxic and anti-influenza potential of ethanolic extract of Moringa oleifera leaves (EEOMOL) and amantadine, an anti-influenza drug, evidenced that this extract showed significantly better (P <0.05) anti-influenza activity (0.78 μg/mL to 100 ug/mL) than amantadine (12.5 ug/mL to 50 ug/mL) (112). Additionally, EEOMOL showed a higher cytotoxic concentration 50 (CC50) (100 μg/mL) than amantadine (50 μg/mL). 115 Based on these observations, it can be inferred that the extract could be a breakthrough in combating future influenza outbreaks, especially those caused by the influenza A (H9) virus, which has shown resistance to amantadine due to mutations in the M2 gene. 3.7 Extract fraction and microorganisms described in Moringa oleifera research Another observation derived from this work is related to the trend that microbiological studies have shown in the past 10 years regarding the type of pathogenic agents and extracts evaluated to reveal the antimicrobial role of the plant. Thus, aqueous and methanolic extracts were used in the highest number of studies ( Figure 4A ), and bacteria were the most studied microorganisms ( Figure 4B ). Figure 4. Compendium of extracts implemented regarding the biological activity of Moringa oleifera on infectious diseases and pathogens studied. A) Extracts B) Pathogens. A noteworthy study in the line of antibacterial research was conducted by Ibrahim et al., 113 who evaluated the antibacterial activities of methanolic and aqueous extracts of Moringa oleifera leaves, with and without heat treatment at 45°C, 50°C, and 55°C for 30 and 60 min, to recreate the cooking and frying conditions to which the plant is subjected when used in the diet. The non-heat-treated extracts showed the ability to inhibit the growth of gram-positive bacteria ( Staphylococcus aureus and Streptococcus agalactiae ) and gram-negative bacteria ( Salmonella typhi and Shigella boydii ), with the methanolic extract showing a high inhibition zone at 150 mg/mL against S. aureus 113 ; the aqueous extract did not show any inhibitory activity against S. agalactiae at a concentration of 125 mg/mL, which was attributed to the presence of low amounts of active constituents, indicating that the antibacterial activity depends on the concentration of the extract and the solvent used. 113 In contrast, the antibacterial activity of the heat-treated extracts was affected. The methanolic extracts maintained their activity against all tested microorganisms after exposure for 60 min at 50°C, while aqueous extracts lost their activity against Shigella boydii but retained it against other microorganisms. 113 Thus, Moringa oleifera could be proposed as an alternative for the control of infections caused by these four bacteria, considering that the thermal treatment of the plant reduces the antimicrobial activity of its phytoconstituents. 4. Conclusions and future perspectives According to the reviewed analyses, the countries with the highest number of studies that met the inclusion and exclusion criteria were India, Malaysia, and Egypt. Regarding the review of in vivo cancer studies, Egypt is the country with the highest number of investigations, with 13 included articles. Similarly, in in vitro studies, Egypt was among the top three countries with the highest number of studies on Moringa oleifera. This indicates that Egypt is committed to finding new and less invasive therapies against cancer than traditional approaches. Furthermore, most studies have focused on liver cancer, which is the leading cause of cancer-related death in the country. Breast cancer is among the most studied neoplasms in the context of this search, which has shown high incidence rates worldwide in recent years. This suggests that researchers, specifically those from Asia and Africa, have been actively seeking alternative treatments to reduce the number of associated cases and deaths. Similar trends have been observed in research conducted in India, although the articles included in this review focused on studying various types of neoplasms, including cervical cancer, which was the third leading cause of death in India in 2020. Indeed, in line with the study of cancer, 2020 saw the highest amount of research conducted worldwide regarding the antitumor and chemopreventive properties of Moringa oleifera , as indicated in Figure 5 . In fact, the study of neoplasms occupied the top position in most of the temporal events that spanned the decade of the study ( Figure 5 ). This clear trend highlights the need for new approaches and generation of new knowledge in this field. Figure 5. Number of worldwide Moringa oleifera publications for the decade from 2010 to 2020. Regarding the study of the potential associated with different parts of the Moringa oleifera , and according to the findings of this complication, it was determined that the leaf is the element that apparently has the greatest biological capacity; therefore, it is the part where most research was focused, which revealed in the context of the study of cancer potential related to cell viability, cytotoxic activity, and antitumor activity in different neoplasms, than the leaf contains various components that benefit human health, which contributes to maintaining a balance between treatment and the patient’s health status. Likewise, it has come to reduce the adverse effects caused by conventional treatments, which positions it as an alternative natural treatment that is still under constant research. Therefore, Moringa oleifera is a promising plant with great potential for cancer treatment, as evidenced in both in vitro and in vivo models, as described in the 60 articles analyzed in this study. This is basically due to the phytochemicals and phenolic compounds, such as quercetin and kaempferol, which allow the development of Moringa biological activities such as inhibition of cell viability through the induction of apoptosis and oxidative stress through the generation of reactive oxygen species (ROS), antiproliferative effects, and antitumor activity. In summary, this plant is a promising therapeutic alternative for cancer treatment. Among the medicinal effects of Moringa oleifera , one of the most remarkable is its hypoglycemic capacity associated with counteracting one of the most relevant chronic illnesses today, diabetes mellitus, a condition that affects millions of people around the world and that does not have a treatment that achieves its definitive cure. However, there are medicines for its control, but these are not easily accessible to the entire population, and Moringa oleifera is widely distributed worldwide. This hypoglycemic effect is directly related to the inhibition of important enzymes, such as α-amylase and α-glucosidase, whose function is to hydrolyze carbohydrates; when these enzymes are inhibited, they delay their absorption, thus decreasing blood glucose levels. On the other hand, this plant also contributes to minimizing the sequelae of diabetes mellitus by controlling oxidative damage in the presence of multiple antioxidants and protects the target organ against damage caused by reactive oxygen species. It also contributes to counteracting the complications of the disease, such as hepatic lesions. In addition to the evident properties of this plant related to chronic diseases, its spectrum of action is not limited to these, as its biological activity has been demonstrated against various microbiological agents. For instance, it has been found that antibacterial activity depends on the concentration of the extract and solvent used. The methanolic extract showed bacterial inhibition, whereas the aqueous extract did not. It is worth noting that antibacterial action has been observed against major pathogens, such as Escherichia coli and Staphylococcus aureus , which are highly prevalent and cause multiple diseases. Leaves and seeds have demonstrated more effective antiviral potential, as is the case against the influenza A virus, but other viral agents have been studied. Leaf extracts exhibit potent and selective inhibition of the first steps in HIV-1 infectivity, which could serve as antiretrovirals for people suffering from HIV/AIDS, who often seek alternative and complementary therapies. As can be seen, there is a wide range of pathologies towards which Moringa oleifera presents important biological activity contributing to counteracting in a similar way to the drugs traditionally used. Despite this, it is necessary to determine the pathology to be treated with a specific dose, as the concentration fluctuates according to various parameters to be controlled. The potential use of Moringa oleifera is more evident because of the large number of studies described in this review. In addition, the safety and toxicity of the products derived from this plant have been intensively analyzed both in vitro and in vivo , and a considerable number of studies in humans have been conducted to demonstrate its therapeutic role in various clinical situations. However, despite all this evidence and certain intrinsic characteristics of the plant with respect to its worldwide availability and low growth requirements, the translation of the biological potential of moringa to clinical practice has not yet materialized, a fact that is evidenced by the scarcity of approved clinical trials on studies related to this plant. While M. oleifera presents a wide range of therapeutic potentials, it is crucial to acknowledge the limitations that may affect its clinical application. Variability in efficacy due to environmental and genetic factors, challenges in standardizing extracts, and concerns about potential toxicity must be thoroughly investigated. For instance, discrepancies in phytochemical content based on geographic origin and cultivation conditions highlight the need for standardized cultivation and extraction protocols to ensure consistent therapeutic outcomes. Moreover, while preclinical studies offer promising results, the translation of these findings into clinical practice requires robust and well-controlled human trials to assess long-term safety and efficacy. These considerations underscore the importance of a cautious and evidence-based approach when evaluating M. oleifera as a therapeutic alternative. M. oleifera is a plant with significant potential as both a therapeutic agent and a tool to address pressing global health challenges, including cancer and antimicrobial resistance. Unlike previous reviews, this work highlights the plant’s dual capacity to target these critical issues while integrating insights from diverse disciplines such as medicine, biotechnology, and phytotherapy. To fully realize the potential of M. oleifera derivatives in modern medicine, it is imperative to expand research efforts in the Western world, complementing the robust evidence already generated in regions with a long-standing tradition of studying this plant. The therapeutic potential of M. oleifera is primarily attributed to its rich profile of phytochemicals and phenolic compounds, including quercetin and kaempferol. These compounds have been shown to modulate critical molecular pathways, such as the induction of apoptosis and oxidative stress through the generation of reactive oxygen species (ROS). Additionally, this review identifies novel evidence regarding its role in inhibiting cell cycle progression, enhancing the immune response, and potentiating the efficacy of conventional treatments in in vitro and in vivo models. Such findings open avenues for developing integrative and complementary therapeutic strategies targeting cancer and other diseases. 134 , 135 Despite the promising evidence regarding M. oleifera’s therapeutic potential, several limitations must be addressed before its widespread clinical application. Variability in its efficacy due to environmental factors, challenges in standardizing extracts, and concerns about potential toxicity remain critical barriers. While numerous in vitro and in vivo studies demonstrate safety and effectiveness, the limited number of approved clinical trials highlights the need for more robust, well-designed research to validate these findings and ensure consistent outcomes in human populations. This study underscores the immense therapeutic potential of M. oleifera as a source of innovative treatments. Future research should explore advanced strategies, such as nanotechnology, to enhance the bioavailability and efficacy of its active compounds. Moreover, integrating this plant into a bioeconomy-based business model could promote sustainable development while addressing global health challenges. By leveraging drug coating and scaffolding technologies, it may be possible to develop synergistic treatment approaches, further expanding the utility of M. oleifera in modern medicine. Ethics and consent Ethical approval and consent were not required. Authors contribution Conceptualization: A. B., B. V., K. M., and A.G.; original draft preparation: A. B, B. V, K.M.; writing: A.B,B.V,K.M, and A. G; editing, reviewing, and formatting: C.A.Z.G. and J.S: and Reviewed drafts of the paper: J.S.; Language editing and preparation of tables and/or figures: K.M., A.G.; Final approval of the review to be published. All the authors have read and agreed to the published version of the manuscript. Data availability Underlying data No underlying data are associated with this article. Extended data Figshare: Data for Biological properties of Moringa oleifera: a review in last decade. https://doi.org/10.6084/m9.figshare.27233943.v3 . 132 , 136 , 137 This project contains following datasets: - dataset_1 - dataset_2 - dataset_3 - Protocol Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0). Reporting guidelines Figshare - PRISMA checklist for “Biological properties of Moringa oleifera: aA systematic review inof the last decade” https://doi.org/10.6084/m9.figshare.27233943.v3 . 132 , 136 , 137 Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0). References 1. Popoola JO, Aworunse OS, Oyesola OL, et al. : A systematic review of pharmacological activities and safety of Moringa oleifera. J. HerbMed. Pharmacol. 2020; 9 (3): 174–190. Publisher Full Text 2. Rahman MM, Mosaddik A, Alam AK: Traditional foods with their constituent’s antiviral and immune system modulating properties. Heliyon. 2021; 7 (1): e05957. PubMed Abstract | Publisher Full Text | Free Full Text 3. Sultana S: Nutritional and functional properties of Moringa oleifera. Metabolism Open. 2020; 8 : 100061. PubMed Abstract | Publisher Full Text | Free Full Text 4. Paikra BK, Gidwani B: Phytochemistry and pharmacology of Moringa oleifera Lam. J. Pharmacopuncture. 2017; 20 (3): 194–200. PubMed Abstract | Publisher Full Text | Free Full Text 5. Doménech Asensi G, Durango Villadiego AM, Ros Berruezo G: Moringa oleifera: Revisión sobre aplicaciones y usos en alimentos. Arch. Latinoam. Nutr. 2017; 67 (2): 86–97. 6. Bhattacharya A, Tiwari P, Sahu PK, et al. : A review of the phytochemical and pharmacological characteristics of Moringa oleifera. J. Pharm. Bioallied Sci. 2018; 10 (4): 181–191. PubMed Abstract | Publisher Full Text | Free Full Text 7. Sreelatha S, Jeyachitra A, Padma P: Antiproliferation and induction of apoptosis by Moringa oleifera leaf extract on human cancer cells. Food Chem. Toxicol. 2011; 49 (6): 1270–1275. PubMed Abstract | Publisher Full Text 8. Hussein MA, Gobba NA, El Bishbishy MH: Composition, in vitro antioxidant and antitumor properties of essential oil from the seeds of Moringa oleifera. Int. J. Pharm. Bio. Sci. 2014; 4 : 532–540. 9. Martín C, Martín G, García A, et al. : Potential applications of Moringa oleifera. A critical review. Pastos y Forrajes. 2013; 36 (2): 137–149. 10. Gopalakrishnan L, Doriya K, Kumar DS: Moringa oleifera: A review on nutritive importance and its medicinal application. Food Sci. Human Wellness. 2016; 5 (2): 49–56. Publisher Full Text 11. Tshabalala T, Ncube B, Madala NE, et al. : Scribbling the cat: a case of the “miracle” plant, Moringa oleifera. Plants. 2019; 8 (11): 510. PubMed Abstract | Publisher Full Text | Free Full Text 12. Sultana B, Anwar F: Flavonols (kaempeferol, quercetin, myricetin) contents of selected fruits, vegetables and medicinal plants. Food Chem. 2008; 108 (3): 879–884. PubMed Abstract | Publisher Full Text 13. Vergara-Jimenez M, Almatrafi MM, Fernandez ML: Bioactive components in Moringa oleifera leaves protect against chronic disease. Antioxidants. 2017; 6 (4): 91. PubMed Abstract | Publisher Full Text | Free Full Text 14. Padla EP, Solis LT, Levida RM, et al. : Antimicrobial isothiocyanates from the seeds of Moringa oleifera Lam. Z Naturforsh. 2012; 67 (11-12): 557–564. PubMed Abstract | Publisher Full Text 15. Rajanandh M, Satishkumar M, Elango K, et al. : A herbal medicine for hyperlipidemia: A preclinical report. Asian Pacific J. Trop. Dis. 2012; 2 : S790–S795. Publisher Full Text 16. Flores-Félix JD, Gonçalves AC, Alves G, et al. : Consumption of phenolic-rich food and dietary supplements as a key tool in SARS-CoV-19 infection. Foods. 2021; 10 (9): 2084. PubMed Abstract | Publisher Full Text | Free Full Text 17. Velázquez-Zavala M, Peón-Escalante IE, Zepeda-Bautista R, et al. : Moringa (Moringa oleifera Lam.): potential uses in agriculture, industry and medicine. Rev. Chapingo Ser. Hortic. 2016; XXII (2): 95–116. Publisher Full Text 18. González Minero FJ: Un estudio transversal de Moringa oleifera Lam.(Moringaceae). Dominguezia. 2018; 5–25. 19. Luqman S, Srivastava S, Kumar R, et al. : Experimental assessment of Moringa oleifera leaf and fruit for its antistress, antioxidant, and scavenging potential using in vitro and in vivo assays. Evid. Based Complementary Altern. Med. 2012; 2012 : 1–12. PubMed Abstract | Publisher Full Text | Free Full Text 20. Santos-Buelga C, Feliciano AS: Flavonoi ds: from structure to health issues. MDPI. 2017; 22 : 477. PubMed Abstract | Publisher Full Text | Free Full Text 21. Nova E, Redondo-Useros N, Martínez-García RM, et al. : Potential of Moringa oleifera to improve glucose control for the prevention of diabetes and related metabolic alterations: a systematic review of animal and human studies. Nutrients. 2020; 12 (7): 2050. PubMed Abstract | Publisher Full Text | Free Full Text 22. Alejandra Sánchez-Muñoz M, Valdez-Solana MA, Campos-Almazán MI, et al. : Streptozotocin-induced adaptive modification of mitochondrial supercomplexes in liver of Wistar rats and the protective effect of Moringa oleifera Lam. Biochem. Res. Int. 2018; 2018 : 1–15. PubMed Abstract | Publisher Full Text | Free Full Text 23. Nandave M, Ojha SK, Joshi S, et al. : Moringa oleifera leaf extract prevents isoproterenol-induced myocardial damage in rats: evidence for an antioxidant, antiperoxidative, and cardioprotective intervention. J. Med. Food. 2009; 12 (1): 47–55. PubMed Abstract | Publisher Full Text 24. Vats S, Gupta T: Evaluation of bioactive compounds and antioxidant potential of hydroethanolic extract of Moringa oleifera Lam. from Rajasthan, India. Physiol. Mol. Biol. Plants. 2017; 23 (1): 239–248. PubMed Abstract | Publisher Full Text | Free Full Text 25. Berkovich L, Earon G, Ron I, et al. : Moringa oleifera aqueous leaf extract down-regulates nuclear factor-kappaB and increases cytotoxic effect of chemotherapy in pancreatic cancer cells. BMC Complement Alter. 2013; 13 (1): 1–7. PubMed Abstract | Publisher Full Text | Free Full Text 26. Shaban A, Mishra GM, Nautiyal R, et al. : In vitro cytotoxicity of Moringa oleifera against different human cancer cell lines. Asian J. Pharm. Clin. Res. 2012; 5 : 271–272. 27. Kou X, Li B, Olayanju JB, et al. : Nutraceutical or pharmacological potential of Moringa oleifera Lam. Nutrients. 2018; 10 (3): 343. PubMed Abstract | Publisher Full Text | Free Full Text 28. WHO: Noncommunicable Diseases.2022 [cited 2022 19-10]. Reference Source 29. PAHO: Noncommunicable diseases.2017 [cited 2022 19-10]. Reference Source 30. WHO: Cancer.2022 [cited 2022 19-10]. Reference Source 31. WHO: Antimicrobial resistance.2020 [cited 2022 19-10]. Reference Source 32. IDF: Diabetes Atlas of the International Diabetes Federation.2019 [cited 2022 19-10]. Reference Source 33. Sun H, Saeedi P, Karuranga S, et al. : IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 2022; 183 : 109119. PubMed Abstract | Publisher Full Text | Free Full Text 34. Aju B, Rajalakshmi R, Mini S: Protective role of Moringa oleifera leaf extract on cardiac antioxidant status and lipid peroxidation in streptozotocin induced diabetic rats. Heliyon. 2019; 5 (12): e02935. PubMed Abstract | Publisher Full Text | Free Full Text 35. Khan W, Parveen R, Chester K, et al. : Hypoglycemic potential of aqueous extract of Moringa oleifera leaf and in vivo GC-MS metabolomics. Front. Pharmacol. 2017; 8 : 577. PubMed Abstract | Publisher Full Text | Free Full Text 36. Jimoh TO: Enzymes inhibitory and radical scavenging potentials of two selected tropical vegetable (Moringa oleifera and Telfairia occidentalis) leaves relevant to type 2 diabetes mellitus. Rev. Bras. 2018; 28 : 73–79. Publisher Full Text 37. Leone A, Bertoli S, Di Lello S, et al. : Effect of Moringa oleifera leaf powder on postprandial blood glucose response: in vivo study on Saharawi people living in refugee camps. Nutrients. 2018; 10 (10): 1494. PubMed Abstract | Publisher Full Text | Free Full Text 38. Aekthammarat D, Tangsucharit P, Pannangpetch P, et al. : Moringa oleifera leaf extract enhances endothelial nitric oxide production leading to relaxation of resistance artery and lowering of arterial blood pressure. Biomed. Pharmacother. 2020; 130 : 110605. PubMed Abstract | Publisher Full Text 39. Al-Malki AL, El Rabey HA: The antidiabetic effect of low doses of Moringa oleifera Lam. seeds on streptozotocin induced diabetes and diabetic nephropathy in male rats. BioMed. Res. Int. 2015; 2015 . PubMed Abstract | Publisher Full Text | Free Full Text 40. Ajayi T, Moody JO, Odumuwagun O, et al. : Lipid Altering Potential of Moringa oleifera Lam Seed Extract and Isolated Constituents In Wistar Rats. Afr. J. Biomed. Res. 2020; 23 (1): 77–85. 41. Barreto S, Báez S, Malvetti V, et al. : Moringa oleifera acute effect on dexamethasone-induced hyperglycemia in Wistar rats. An Fac Cienc Méd. 2015; 48 (1): 41–48. Publisher Full Text 42. Vargas-Tineo OW, Segura-Muñoz DM, Becerra-Gutiérrez LK, et al. : Efecto hipoglicemiante de Moringa oleifera (moringa) comparado con Smallanthus Sonchifolius (yacón) en Rattus norvegicus con diabetes mellitus inducida. Rev. Peru Med. Exp. Salud Publica. 2020; 37 : 478–484. PubMed Abstract | Publisher Full Text 43. Bamagous GA, Al Ghamdi SS, Ibrahim IAA, et al. : Antidiabetic and antioxidant activity of ethyl acetate extract fraction of Moringa oleifera leaves in streptozotocin-induced diabetes rats via inhibition of inflammatory mediators. Asian Pac. J. Trop. Biomed. 2018; 8 (6): 320. Publisher Full Text 44. Tariq A, Sadia S, Pan K, et al. : A systematic review on ethnomedicines of anti-cancer plants. Phytother. Res. 2017; 31 (2): 202–264. Publisher Full Text 45. Randriamboavonjy JI, Loirand G, Vaillant N, et al. : Cardiac protective effects of Moringa oleifera seeds in spontaneous hypertensive rats. Am. J. Hypertens. 2016; 29 (7): 873–881. PubMed Abstract | Publisher Full Text 46. Soliman MM, Aldhahrani A, Alkhedaide A, et al. : The ameliorative impacts of Moringa oleifera leaf extract against oxidative stress and methotrexate-induced hepato-renal dysfunction. Biomed. Pharmacother. 2020; 128 : 110259. PubMed Abstract | Publisher Full Text 47. Abou-Zeid SM, Ahmed AI, Awad A, et al. : Moringa oleifera ethanolic extract attenuates tilmicosin-induced renal damage in male rats via suppression of oxidative stress, inflammatory injury, and intermediate filament proteins mRNA expression. Biomed. Pharmacother. 2021; 133 : 110997. PubMed Abstract | Publisher Full Text 48. Nafiu AO, Akomolafe RO, Alabi QK, et al. : Effect of fatty acids from ethanol extract of Moringa oleifera seeds on kidney function impairment and oxidative stress induced by gentamicin in rats. Biomed. Pharmacother. 2019; 117 : 109154. PubMed Abstract | Publisher Full Text 49. Nahar S, Faisal FM, Iqbal J, et al. : Antiobesity activity of Moringa oleifera leaves against high fat diet-induced obesity in rats. Int. J. Basic. Clin. Pharmacol. 2016; 5 : 1263–1268. Publisher Full Text 50. Metwally FM, Rashad HM, Ahmed HH, et al. : Molecular mechanisms of the anti-obesity potential effect of Moringa oleifera in the experimental model. Asian Pac. J. Trop. Biomed. 2017; 7 (3): 214–221. Publisher Full Text 51. Mabrouki L, Rjeibi I, Taleb J, et al. : Cardiac ameliorative effect of Moringa oleifera leaf extract in high-fat diet-induced obesity in rat model. BioMed. Res. Int. 2020; 2020 . PubMed Abstract | Publisher Full Text | Free Full Text 52. Mahdi HJ, Khan NAK, Asmawi MZB, et al. : In vivo anti-arthritic and anti-nociceptive effects of ethanol extract of Moringa oleifera leaves on complete Freund’s adjuvant (CFA)-induced arthritis in rats. Integr. Med. Res. 2018; 7 (1): 85–94. PubMed Abstract | Publisher Full Text | Free Full Text 53. Muhammed RE, El-Desouky MA, Abo-Seda SB, et al. : The protecting role of Moringa oleifera in cypermethrin-induced mitochondrial dysfunction and apoptotic events in rats brain. J. King Saud. Univ. Sci. 2020; 32 (6): 2717–2722. Publisher Full Text 54. Igado OO, Andrioli A, Azeez IA, et al. : The ameliorative effects of a phenolic derivative of Moringa oleifera leave against vanadium-induced neurotoxicity in mice. IBRO Rep. 2020; 9 : 164–182. PubMed Abstract | Publisher Full Text | Free Full Text 55. Mohamed AA-R, Metwally MM, Khalil SR, et al. : Moringa oleifera extract attenuates the CoCl2 induced hypoxia of rat’s brain: expression pattern of HIF-1α, NF-kB, MAO and EPO. Biomed. Pharmacother. 2019; 109 : 1688–1697. PubMed Abstract | Publisher Full Text 56. Sheikh A, Yeasmin F, Agarwal S, et al. : Protective effects of Moringa oleifera Lam. leaves against arsenic-induced toxicity in mice. Asian Pac. J. Trop. Biomed. 2014; 4 : S353–S358. PubMed Abstract | Publisher Full Text | Free Full Text 57. Fathy SM, Mahmoud MS, Moringa oleifera Lam.: leaf extract mitigates carbon tetrachloride-mediated hepatic inflammation and apoptosis via targeting oxidative stress and toll-like receptor 4/nuclear factor kappa B pathway in mice. Food Sci. Human Wellness. 2021; 10 (3): 383–391. Publisher Full Text 58. Muzumbukilwa WT, Nlooto M, Owira PMO: Hepatoprotective effects of Moringa oleifera Lam (Moringaceae) leaf extracts in streptozotocin-induced diabetes in rats. J. Funct. Foods. 2019; 57 : 75–82. Publisher Full Text 59. Sung H, Ferlay J, Siegel RL, et al. : Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021; 71 (3): 209–249. PubMed Abstract | Publisher Full Text 60. PAHO: Country Cancer Profiles.2020 [cited 2022 19-10]. Reference Source 61. Bang Y-J, Van Cutsem E, Feyereislova A, et al. : Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376 (9742): 687–697. PubMed Abstract | Publisher Full Text 62. Cuellar-Núñez ML, Loarca-Piña G, Berhow M, et al. : Glucosinolate-rich hydrolyzed extract from Moringa oleifera leaves decreased the production of TNF-α and IL-1β cytokines and induced ROS and apoptosis in human colon cancer cells. J. Funct. Foods. 2020; 75 : 104270. Publisher Full Text 63. Do BH, Nguyen TPT, Ho NQC, et al. : Mitochondria-mediated Caspase-dependent and Caspase-independent apoptosis induced by aqueous extract from Moringa oleifera leaves in human melanoma cells. Mol. Biol. Rep. 2020; 47 (5): 3675–3689. PubMed Abstract | Publisher Full Text 64. Adebayo IA, Arsad H, Samian MR: Antiproliferative effect on breast cancer (MCF7) of Moringa oleifera seed extracts. Afr. J. Tradit. Complement. Altern. Med. 2017; 14 (2): 282–287. PubMed Abstract | Publisher Full Text | Free Full Text 65. Al-Asmari AK, Albalawi SM, Athar MT, et al. : Moringa oleifera as an anti-cancer agent against breast and colorectal cancer cell lines. PLoS One. 2015; 10 (8): e0135814. PubMed Abstract | Publisher Full Text | Free Full Text 66. Barhoi D, Upadhaya P, Barbhuiya SN, et al. : Aqueous extract of Moringa oleifera exhibit potential anticancer activity and can be used as a possible cancer therapeutic agent: a study involving in vitro and in vivo approach. J. Am. Coll. Nutr. 2021; 40 (1): 70–85. PubMed Abstract | Publisher Full Text 67. Nair S, Varalakshmi K: Anticancer, cytotoxic potential of Moringa oleifera extracts on HeLa cell line. J Nat Pharm. 2011; 2 (3): 138–142. Publisher Full Text 68. de Siqueira Patriota LL , Ramos DBM, Dos Santos ACLA, et al. : Antitumor activity of Moringa oleifera (drumstick tree) flower trypsin inhibitor (MoFTI) in sarcoma 180-bearing mice. Food Chem. Toxicol. 2020; 145 : 111691. PubMed Abstract | Publisher Full Text 69. Elsayed EA, Sharaf-Eldin MA, Wadaan M: In vitro evaluation of cytotoxic activities of essential oil from Moringa oleifera seeds on HeLa, HepG2, MCF-7, CACO-2 and L929 cell lines. Asian Pac. J. Cancer Prev. 2015; 16 (11): 4671–4675. PubMed Abstract | Publisher Full Text 70. Fernandes EE, Pulwale AV, Patil GA, et al. : Probing regenerative potential of Moringa oleifera aqueous extracts using in vitro cellular assays. Pharm. Res. 2016; 8 (4): 231–237. PubMed Abstract | Publisher Full Text | Free Full Text 71. Anand K, Tiloke C, Phulukdaree A, et al. : Biosynthesis of palladium nanoparticles by using Moringa oleifera flower extract and their catalytic and biological properties. J. Photochem. Photobiol. B Biol. 2016; 165 : 87–95. PubMed Abstract | Publisher Full Text 72. Xie J, Luo F-x, Shi C-y, et al. : Moringa oleifera alkaloids inhibited PC3 cells growth and migration through the COX-2 mediated wnt/β-catenin signaling pathway. Front. Pharmacol. 2020; 11 : 523962. PubMed Abstract | Publisher Full Text | Free Full Text 73. Akanni E, Adedeji A, Akanni R, et al. : Up-regulation of TNF-α by ethanol extract of Moringa oleifera in benzene-induced leukemic wister rat: A possible mechanism of anticancer property. RRJoOH. 2014; 74 : 3721–3792. Publisher Full Text 74. Reda F, Borjac J, Fakhouri R, et al. : Cytotoxic effect of Moringa oleiferaon colon cancer cell lines. Acta Hortic. 2017; 1158 : 269–278. Publisher Full Text 75. García-Beltrán JM, Mansour AT, Alsaqufi AS, et al. : Effects of aqueous and ethanolic leaf extracts from drumstick tree (Moringa oleifera) on gilthead seabream (Sparus aurata L.) leucocytes, and their cytotoxic, antitumor, bactericidal and antioxidant activities. Fish Shellfish Immunol. 2020; 106 : 44–55. PubMed Abstract | Publisher Full Text 76. Pandey P, Khan F: Jab1 inhibition by methanolic extract of Moringa oleifera leaves in cervical cancer cells: a potent targeted therapeutic approach. Nutr. Cancer. 2021; 73 (11-12): 2411–2419. PubMed Abstract | Publisher Full Text 77. Gaffar S, Apriani R, Herlina T: n-Hexane fraction of Moringa oleifera Lam. leaves induces apoptosis and cell cycle arrest on T47D breast cancer cell line. J. Pharm. Pharmacogn. Res. 2019; 7 (3): 173–183. Publisher Full Text 78. Madi N, Dany M, Abdoun S, et al. : Moringa oleifera’s nutritious aqueous leaf extract has anticancerous effects by compromising mitochondrial viability in an ROS-dependent manner. J. Am. Coll. Nutr. 2016; 35 (7): 604–613. PubMed Abstract | Publisher Full Text 79. Sun C, Li W, Liu Y, et al. : In vitro/in vivo hepatoprotective properties of 1-O-(4-hydroxymethylphenyl)-α-L-rhamnopyranoside from Moringa oleifera seeds against carbon tetrachloride-induced hepatic injury. Food Chem. Toxicol. 2019; 131 : 110531. PubMed Abstract | Publisher Full Text 80. de Andrade Luz L , Rossato FA, e Costa RAP, et al. : Cytotoxicity of the coagulant Moringa oleifera lectin (cMoL) to B16-F10 melanoma cells. Toxicol In Vitro. 2017; 44 : 94–99. PubMed Abstract | Publisher Full Text 81. Abd-Rabou AA, Abdalla AM, Ali NA, et al. : Moringa oleifera root induces cancer apoptosis more effectively than leave nanocomposites and its free counterpart. Asian Pac. J. Cancer Prev. 2017; 18 (8): 2141–2149. PubMed Abstract 82. Tiloke C, Phulukdaree A, Chuturgoon AA: The antiproliferative effect of Moringa oleifera crude aqueous leaf extract on cancerous human alveolar epithelial cells. BMC Complement. Alter. 2013; 13 (1): 1–8. PubMed Abstract | Publisher Full Text | Free Full Text 83. Siddiqui S, Upadhyay S, Ahmad I, et al. : Cytotoxicity of Moringa oleifera fruits on human liver cancer and molecular docking analysis of bioactive constituents against caspase-3 enzyme. J. Food Biochem. 2021; 45 (5): e13720. PubMed Abstract | Publisher Full Text 84. Jung IL: Soluble extract from Moringa oleifera leaves with a new anticancer activity. PLoS One. 2014; 9 (4): e95492. PubMed Abstract | Publisher Full Text | Free Full Text 85. Jaafaru MS, Abd Karim NA, Mohamed Eliaser E, et al. : Nontoxic glucomoringin-isothiocyanate (GMG-ITC) rich soluble extract induces apoptosis and inhibits proliferation of human prostate adenocarcinoma cells (PC-3). Nutrients. 2018; 10 (9): 1174. PubMed Abstract | Publisher Full Text | Free Full Text 86. Jung IL, Lee JH, Kang SC: A potential oral anticancer drug candidate, Moringa oleifera leaf extract, induces the apoptosis of human hepatocellular carcinoma cells. Oncol. Lett. 2015; 10 (3): 1597–1604. PubMed Abstract | Publisher Full Text | Free Full Text 87. Luetragoon T, Pankla Sranujit R, Noysang C, et al. : Anti-Cancer effect of 3-Hydroxy-β-Ionone identified from Moringa oleifera Lam. Leaf on human squamous cell carcinoma 15 cell line. Molecules. 2020; 25 (16): 3563. PubMed Abstract | Publisher Full Text | Free Full Text 88. Krishnamurthy PT, Vardarajalu A, Wadhwani A, et al. : Identification and characterization of a potent anticancer fraction from the leaf extracts of Moringa oleifera L. Indian J. Exp. Biol. 2015; 53 : 98–103. PubMed Abstract 89. Khalafalla MM, Abdellatef E, Dafalla HM, et al. : Active principle from Moringa oleifera Lam leaves effective against two leukemias and a hepatocarcinoma. Afr. J. Biotechnol. 2010; 9 (49): 8467–8471. 90. Suphachai C: Antioxidant and anticancer activities of Moringa oleifera leaves. J. Med. Plant Res. 2014; 8 (7): 318–325. Publisher Full Text 91. Diab KA, Guru SK, Bhushan S, et al. : In vitro anticancer activities of Anogeissus latifolia, Terminalia bellerica, Acacia catechu and Moringa oleiferna Indian plants. Asian Pac. J. Cancer Prev. 2015; 16 (15): 6423–6428. PubMed Abstract | Publisher Full Text 92. Cuellar-Núñez M, de Mejia EG , Loarca-Pina G: Moringa oleifera leaves alleviated inflammation through downregulation of IL-2, IL-6, and TNF-α in a colitis-associated colorectal cancer model. Food Res. Int. 2021; 144 : 110318. PubMed Abstract | Publisher Full Text 93. Arif M, Yustisia I: The combination from ethanol extract of moringa leaves (Moringa oleifera L.) and ethanol extract of papaya leaves (Carica papaya L.) slows the tumor growth in sprague dawley rats induced 7, 12-dimethylbenz (a) anthracene. MPC. 2020; 3 : 100100. Publisher Full Text 94. Sadek KM, Abouzed TK, Abouelkhair R, et al. : The chemo-prophylactic efficacy of an ethanol Moringa oleifera leaf extract against hepatocellular carcinoma in rats. Pharm. Biol. 2017; 55 (1): 1458–1466. PubMed Abstract | Publisher Full Text | Free Full Text 95. Khalil SR, El Bohi KM, Khater S, et al. : Moringa oleifera leaves ethanolic extract influences DNA damage signaling pathways to protect liver tissue from cobalt-triggered apoptosis in rats. Ecotoxicol. Environ. Saf. 2020; 200 : 110716. PubMed Abstract | Publisher Full Text 96. Ali FT, Hassan NS, Abdrabou RR: Hepatoprotective and antiproliferative activity of moringinine, chlorogenic acid and quercetin. IJRMS. 2016; 4 (4): 1147–1153. Publisher Full Text 97. Cuellar-Nuñez M, Luzardo-Ocampo I, Campos-Vega R, et al. : Physicochemical and nutraceutical properties of moringa (Moringa oleifera) leaves and their effects in an in vivo AOM/DSS-induced colorectal carcinogenesis model. Food Res. Int. 2018; 105 : 159–168. PubMed Abstract | Publisher Full Text 98. Hagoel L, Vexler A, Kalich-Philosoph L, et al. : Combined effect of Moringa oleifera and ionizing radiation on survival and metastatic activity of pancreatic cancer cells. Integr. Cancer Ther. 2019; 18 : 1534735419828829. PubMed Abstract | Publisher Full Text | Free Full Text 99. Budda S, Butryee C, Tuntipopipat S, et al. : Suppressive effects of Moringa oleifera Lam pod against mouse colon carcinogenesis induced by azoxymethane and dextran sodium sulfate. Asian Pac. J. Cancer Prev. 2011; 12 (12): 3221–3228. PubMed Abstract 100. Purwal L, Pathak A, Jain U: In vivo anticancer activity of the leaves and fruits of Moringa oleifera on mouse melanoma. Pharmacologyonline. 2010; 1 : 655–665. 101. Kraiphet S, Butryee C, Rungsipipat A, et al. : Apoptosis induced by Moringa oleifera Lam. pod in mouse colon carcinoma model. Comp. Clin. Pathol. 2018; 27 (1): 21–30. Publisher Full Text 102. Araújo LCC, Aguiar JS, Napoleão TH, et al. : Evaluation of cytotoxic and anti-inflammatory activities of extracts and lectins from Moringa oleifera seeds. PLoS One. 2013; 8 (12): e81973. PubMed Abstract | Publisher Full Text | Free Full Text 103. Lim WF, Mohamad Yusof MI, Teh LK, et al. : Significant decreased expressions of CaN, VEGF, SLC39A6 and SFRP1 in MDA-MB-231 xenograft breast tumor mice treated with Moringa oleifera leaves and seed residue (MOLSr) extracts. Nutrients. 2020; 12 (10): 2993. PubMed Abstract | Publisher Full Text | Free Full Text 104. Organization WH: Global action plan on antimicrobial resistance.2015. 105. Stohs SJ, Hartman MJ: Review of the Safety and Efficacy of Moringa oleifera. Phytother. Res. 2015; 29 (6): 796–804. PubMed Abstract | Publisher Full Text | Free Full Text 106. Abd Rani NZ, Husain K, Kumolosasi E: Moringa Genus: A Review of Phytochemistry and Pharmacology. Front. Pharmacol. 2018; 9 : 108. PubMed Abstract | Publisher Full Text | Free Full Text 107. Gopalakrishnan L, Doriya K, Kumar D: Moringa oleifera: A review on nutritive importance and its medicinal application. Food Sci. Hum. Wellness. 2016; 5 (2): 49–56. Publisher Full Text 108. Dzotam JK, Touani FK, Kuete V: Antibacterial and antibiotic-modifying activities of three food plants (Xanthosoma mafaffa Lam., Moringa oleifera (L.) Schott and Passiflora edulis Sims) against multidrug-resistant (MDR) Gram-negative bacteria. BMC Complement. Alter. 2015; 16 (1): 8–9. PubMed Abstract | Publisher Full Text | Free Full Text 109. Umamaheswari A, SJ GF.: Investigation on the biofilm eradication potential of selected medicinal plants against methicillin-resistant Staphylococcus aureus. Biotechnol. Rep. 2020; 28 : e00523. PubMed Abstract | Publisher Full Text | Free Full Text 110. Nworu C, Okoye E, Ezeifeka G, et al. : Extracts of Moringa oleifera Lam. showing inhibitory activity against early steps in the infectivity of HIV-1 lentiviral particles in a viral vector-based screening. Afr. J. Biotechnol. 2013; 12 (30): 4866–4873. Publisher Full Text 111. Cudjoe E, Donu D, Okonu RE, et al. : The in vitro Antiplasmodial Activities of Aqueous Extracts of Selected Ghanaian Herbal Plants. J. Parasitol. Res. 2020; 2020 : 1–8. PubMed Abstract | Publisher Full Text | Free Full Text 112. Tiwari Pandey A, Pandey I, Zamboni P, et al. : Traditional herbal remedies with a multifunctional therapeutic approach as an implication in COVID-19 associated co-infections. Coatings. 2020; 10 (8): 761. Publisher Full Text 113. Ibrahim N, Kebede A: In vitro antibacterial activities of methanol and aqueous leave extracts of selected medicinal plants against human pathogenic bacteria. Saudi J. Biol. Sci. 2020; 27 (9): 2261–2268. PubMed Abstract | Publisher Full Text | Free Full Text 114. Akpor OB, Ndakotsu J, Evbuomwan IO, et al. : Bacterial growth inhibition and antioxidant potentials of leaf infusions of (Moringa oleifera), locust beans (Parkia biglobosa) and bitter leaf (Vernonia amygladina). Sci Afr. 2021; 14 : e01001. Publisher Full Text 115. Ashraf M, Alam SS, Fatima M, et al. : Comparative anti-influenza potential of Moringa oleifera leaves and amantadine invitro. Pak. Postgraduate Med. J. 2017; 28 (4): 127–131. Publisher Full Text 116. Hammi K, Essid R, Tabbene O, et al. : Antileishmanial activity of Moringa oleifera leaf extracts and potential synergy with amphotericin B. S. Afr. J. Bot. 2020; 129 : 67–73. Publisher Full Text 117. Nasr-Eldin MA, Abdelhamid A, Baraka D: Antibiofilm and antiviral potential of leaf extracts from Moringa oleifera and rosemary (Rosmarinus officinalis Lam.). Egypt. J. Microbiol. 2017; (1): 129–139. Publisher Full Text 118. Sohaib M, Al-Barakah FN, Migdadi HM, et al. : Comparative study among Avicennia marina, Phragmites australis, and Moringa oleifera based ethanolic-extracts for their antimicrobial, antioxidant, and cytotoxic activities. Saudi J. Biol. Sci. 2022; 29 (1): 111–122. PubMed Abstract | Publisher Full Text | Free Full Text 119. Putri GE, Rilda Y, Syukri S, et al. : Highly antimicrobial activity of cerium oxide nanoparticles synthesized using Moringa oleifera leaf extract by a rapid green precipitation method. J. Mater. Res. Technol. 2021; 15 : 2355–2364. Publisher Full Text 120. Das PE, Abu-Yousef IA, Majdalawieh AF, et al. : Green synthesis of encapsulated copper nanoparticles using a hydroalcoholic extract of Moringa oleifera leaves and assessment of their antioxidant and antimicrobial activities. Molecules. 2020; 25 (3): 555. PubMed Abstract | Publisher Full Text | Free Full Text 121. Das PE, Majdalawieh AF, Abu-Yousef IA, et al. : Use of a hydroalcoholic extract of Moringa oleifera leaves for the green synthesis of bismuth nanoparticles and evaluation of their anti-microbial and antioxidant activities. Materials. 2020; 13 (4): 876. PubMed Abstract | Publisher Full Text | Free Full Text 122. Kalaiselvi V, Mathammal R, Vijayakumar S, et al. : Microwave assisted green synthesis of Hydroxyapatite nanorods using Moringa oleifera flower extract and its antimicrobial applications. Int. J. Vet. Sci. 2018; 6 (2): 286–295. PubMed Abstract | Publisher Full Text | Free Full Text 123. Nova ICV, Moreira LR, Torres DJL, et al. : A trypsin inhibitor from Moringa oleifera flowers modulates the immune response in vitro of Trypanosoma cruzi-infected human cells. Antibiotics. 2020; 9 (8): 515. PubMed Abstract | Publisher Full Text | Free Full Text 124. Pontual EV, Pires-Neto DF, Fraige K, et al. : A trypsin inhibitor from Moringa oleifera flower extract is cytotoxic to Trypanosoma cruzi with high selectivity over mammalian cells. Nat. Prod. Res. 2018; 32 (24): 2940–2944. PubMed Abstract | Publisher Full Text 125. Bindhu M, Umadevi M, Esmail GA, et al. : Green synthesis and characterization of silver nanoparticles from Moringa oleifera flower and assessment of antimicrobial and sensing properties. J. Photochem. Photobiol. B Biol. 2020; 205 : 111836. PubMed Abstract | Publisher Full Text 126. Xiong Y, Rajoka MSR, Mehwish HM, et al. : Virucidal activity of Moringa A from Moringa oleifera seeds against Influenza A Viruses by regulating TFEB. Int. Immunopharmacol. 2021; 95 : 107561. PubMed Abstract | Publisher Full Text 127. Kandil OM, Hassan NM, Sedky D, et al. : Anthelmintic efficacy of Moringa oleifera seed methanolic extract against Fasciola hepatica. J. Parasit. Dis. 2018; 42 (3): 391–401. PubMed Abstract | Publisher Full Text | Free Full Text 128. Shaji D, Yamamoto S, Saito R, et al. : Proposal of novel natural inhibitors of severe acute respiratory syndrome coronavirus 2 main protease: Molecular docking and ab initio fragment molecular orbital calculations. Biophys. Chem. 2021; 275 : 106608. PubMed Abstract | Publisher Full Text | Free Full Text 129. Sivani BM, Venkatesh P, Murthy TK, et al. : In silico screening of antiviral compounds from Moringa oleifera for inhibition of SARS-CoV-2 main protease. Curr. Opin. Green Sustain. Chem. 2021; 4 : 100202. Publisher Full Text 130. Umar HI, Josiah SS, Saliu TP, et al. : In-silico analysis of the inhibition of the SARS-CoV-2 main protease by some active compounds from selected African plants. J. Taibah Univ. Medical Sci. 2021; 16 (2): 162–176. PubMed Abstract | Publisher Full Text | Free Full Text 131. Oyedara OO, Agbedahunsi JM, Adeyemi FM, et al. : Computational screening of phytochemicals from three medicinal plants as inhibitors of transmembrane protease serine 2 implicated in SARS-CoV-2 infection. Phytomed. Plus. 2021; 1 (4): 100135. PubMed Abstract | Publisher Full Text | Free Full Text 132. Soto AJ, Gomez AC, Vasquez BM, et al. : A Biological properties of Moringa oleifera: a review in the last decade. Publisher Full Text 133. Muhammad S, Hassan SH, Al-Sehemi AG, et al. : Exploring the new potential antiviral constituents of Moringa oliefera for SARS-COV-2 pathogenesis: An in silico molecular docking and dynamic studies. Chem. Phys. Lett. 2021; 767 : 138379. PubMed Abstract | Publisher Full Text | Free Full Text 134. Zuniga-Gonzalez CA: TFP Bioeconomy Impact post Covid-19 on the agricultural economy. PLoS One. 2023; 18 (11): e0288885. PubMed Abstract | Publisher Full Text | Free Full Text 135. Zuniga Gonzalez CA, Jaramillo-Villanueva JL: Frontier model of the environmental inefficiency effects on livestock bioeconomy [version 3; peer review: 3 approved, 1 not approved]. F1000Res. 2024; 11 : 1382. PubMed Abstract | Publisher Full Text | Free Full Text 136. Liberati A, Altman DG, Tetzlaff J, et al. : The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6 : e1000100. PubMed Abstract | Publisher Full Text | Free Full Text 137. Soto JA, Gomez AC, Vásquez BM, et al. : Data for Biological properties of Moringa oleifera: a review in last decade. Dataset. figshare. 2024. Publisher Full Text Comments on this article Comments (0) Version 2 VERSION 2 PUBLISHED 19 Nov 2024 ADD YOUR COMMENT Comment Author details Author details 1 Facultad de Ciencias Médicas y de la Salud, Instituto de Investigación Masira, University of Santander, Bucaramanga, Santander, 540003, Colombia 2 Area of knowledge of Agrarian and Veterinary Sciences Research Centre, Bioeconomy and Climate Change Unit Research, National Autonomous University of Nicaragua, Leon, Leon, Leon, 21000, Nicaragua Javier Andrés Soto Roles: Conceptualization, Formal Analysis, Methodology, Supervision, Validation Andrea Catalina Gómez Roles: Conceptualization, Investigation Maryeli Vásquez Roles: Investigation Andrea Natalia Barreto Roles: Conceptualization, Investigation Karen Shirley Molina Roles: Conceptualization, Investigation C. A. Zuniga-Gonzalez Roles: Visualization, Writing – Original Draft Preparation, Writing – Review & Editing Competing interests No competing interests were disclosed. Grant information The author(s) declared that no grants were involved in supporting this work. Article Versions (2) version 2 Revised Published: 30 Jan 2025, 13:1390 https://doi.org/10.12688/f1000research.157194.2 version 1 Published: 19 Nov 2024, 13:1390 https://doi.org/10.12688/f1000research.157194.1 Copyright © 2025 Soto JA et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Download Export To Sciwheel Bibtex EndNote ProCite Ref. Manager (RIS) Sente metrics Views Downloads F1000Research - - PubMed Central info_outline Data from PMC are received and updated monthly. - - Citations open_in_new 0 open_in_new 0 open_in_new SEE MORE DETAILS CITE how to cite this article Soto JA, Gómez AC, Vásquez M et al. Biological properties of Moringa oleifera : A systematic review of the last decade [version 2; peer review: 3 approved] . F1000Research 2025, 13 :1390 ( https://doi.org/10.12688/f1000research.157194.2 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS track receive updates on this article Track an article to receive email alerts on any updates to this article. TRACK THIS ARTICLE Share Open Peer Review Current Reviewer Status: ? Key to Reviewer Statuses VIEW HIDE Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Version 2 VERSION 2 PUBLISHED 30 Jan 2025 Revised Views 0 Cite How to cite this report: Carvajal Alcaraz M. Reviewer Report For: Biological properties of Moringa oleifera : A systematic review of the last decade [version 2; peer review: 3 approved] . F1000Research 2025, 13 :1390 ( https://doi.org/10.5256/f1000research.177200.r363555 ) The direct URL for this report is: https://f1000research.com/articles/13-1390/v2#referee-response-363555 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 22 Feb 2025 Micaela Carvajal Alcaraz , CEBAS-CSIC. Campus Universitario de Espinardo, Murcia, Spain Approved VIEWS 0 https://doi.org/10.5256/f1000research.177200.r363555 The authors have thoroughly addressed all concerns raised in the manuscript. Specifically, they have clearly established the novelty and added value of this review by emphasizing its unique focus on the dual potential of Moringa oleifera in combating both cancer ... Continue reading READ ALL The authors have thoroughly addressed all concerns raised in the manuscript. Specifically, they have clearly established the novelty and added value of this review by emphasizing its unique focus on the dual potential of Moringa oleifera in combating both cancer and antimicrobial resistance. Additionally, they have integrated data from multiple disciplines, including medicine, biotechnology, and phytotherapy, providing a broader perspective than previous reviews. The discussion has been expanded to highlight newly identified mechanisms, pathways, and potential clinical applications not extensively covered in prior literature. Furthermore, the conclusions have been revised to ensure a balanced perspective, incorporating a discussion of possible limitations such as toxicity, variability in efficacy, and challenges in standardizing extracts. Competing Interests: No competing interests were disclosed. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Carvajal Alcaraz M. Reviewer Report For: Biological properties of Moringa oleifera : A systematic review of the last decade [version 2; peer review: 3 approved] . F1000Research 2025, 13 :1390 ( https://doi.org/10.5256/f1000research.177200.r363555 ) The direct URL for this report is: https://f1000research.com/articles/13-1390/v2#referee-response-363555 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Respond or Comment COMMENT ON THIS REPORT Version 1 VERSION 1 PUBLISHED 19 Nov 2024 Views 0 Cite How to cite this report: Singh P. Reviewer Report For: Biological properties of Moringa oleifera : A systematic review of the last decade [version 2; peer review: 3 approved] . F1000Research 2025, 13 :1390 ( https://doi.org/10.5256/f1000research.172612.r355211 ) The direct URL for this report is: https://f1000research.com/articles/13-1390/v1#referee-response-355211 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 30 Jan 2025 Pradeep Singh , Debre Tabor University, Debre Tabor, Amhara, Ethiopia Approved VIEWS 0 https://doi.org/10.5256/f1000research.172612.r355211 Biological properties of Moringa oleifera : A systematic review of the last decade This review examines original research papers on Moringa oleifera published from 2010 to 2021. The papers focus on biological properties, especially antitumor activity and possible uses against chronic ... Continue reading READ ALL Biological properties of Moringa oleifera : A systematic review of the last decade This review examines original research papers on Moringa oleifera published from 2010 to 2021. The papers focus on biological properties, especially antitumor activity and possible uses against chronic and infectious diseases. The authors gave in-depth pharmacognostical descriptions and phytochemicals from different parts of Moringa oleifera. They also talked about the plant's traditional uses, antioxidant effects, and potential to fight cancer. activity. The systematic review is compiled by collecting original research articles from various databases like PubMed, Scopus, and Google Scholar. The method used to put this together was very detailed. First, 2700 publications were found in databases. These were then screened to find 410 articles that met certain criteria, such as having to do with Moringa oleifera, chronic diseases, infectious diseases, biological activity, human cancer, antitumor biological activity, in vivo and in vitro activity, and anticancer properties. Finally, 129 (134 listed in reference section) publications were chosen to be included in the final draft of the systematic review. This compilation excludes previously published reviews, editorials, and articles published in languages other than English and Spanish. Suggestions Abbreviations like MO, MOE, and MOSE for Moringa oleifera should be used wisely, and uniformity must be maintained throughout the article. Authors can use an abbreviation once at the beginning of the article with a full description, and then only use the abbreviation for further references. The numbers of publications used for this compilation should be the same. Please check 129 publications mentioned in the abstract, 112 written in the second paragraph of the method section, and a total of 134 references listed under the reference section. Authors must review English grammar and sentence construction. As mentioned below, recheck references for duplication. 129. Soto AJ, Gomez AC, Vasquez BM, et al. : A Biological properties of Moringa oleifera: a review in the last decade. Publisher Full Text 134. Soto JA, Gomez AC, Vásquez BM, et al. : Data for Biological properties of Moringa oleifera: a review in last decade. Dataset. figshare. 2024. Publisher Full Text Are the rationale for, and objectives of, the Systematic Review clearly stated? Yes Are sufficient details of the methods and analysis provided to allow replication by others? Yes Is the statistical analysis and its interpretation appropriate? Not applicable Are the conclusions drawn adequately supported by the results presented in the review? Yes If this is a Living Systematic Review, is the ‘living’ method appropriate and is the search schedule clearly defined and justified? (‘Living Systematic Review’ or a variation of this term should be included in the title.) No Competing Interests: No competing interests were disclosed. Reviewer Expertise: Pharmacognosy & Phytochemistry I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Singh P. Reviewer Report For: Biological properties of Moringa oleifera : A systematic review of the last decade [version 2; peer review: 3 approved] . F1000Research 2025, 13 :1390 ( https://doi.org/10.5256/f1000research.172612.r355211 ) The direct URL for this report is: https://f1000research.com/articles/13-1390/v1#referee-response-355211 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 05 Feb 2025 C. A. Zuniga-Gonzalez , Area of knowledge of Agrarian and Veterinary Sciences. Agroecology, National Autonomous University of Nicaragua, Leon, Leon, 21000, Nicaragua 05 Feb 2025 Author Response Dear Reviewer 3, I sincerely appreciate your valuable feedback and observations. I have carefully reviewed your suggestions and made the necessary revisions in version 2 of the manuscript to improve ... Continue reading Dear Reviewer 3, I sincerely appreciate your valuable feedback and observations. I have carefully reviewed your suggestions and made the necessary revisions in version 2 of the manuscript to improve its clarity and accuracy. First, I have standardized the use of abbreviations for Moringa oleifera (MO, MOE, and MOSE), following your recommendation to ensure consistency throughout the text. I have also corrected the discrepancy in the number of publications mentioned in the abstract, methods section, and reference list, ensuring uniformity in the data presented. Furthermore, I have thoroughly reviewed the English grammar and sentence structure as you suggested, to enhance the flow and readability of the manuscript. Additionally, I have checked and corrected the duplicated references you pointed out, ensuring accuracy and consistency in citation. Thank you once again for your attention to detail. Your feedback has been extremely helpful in improving the quality of the manuscript. Sincerely, Carlos Dear Reviewer 3, I sincerely appreciate your valuable feedback and observations. I have carefully reviewed your suggestions and made the necessary revisions in version 2 of the manuscript to improve its clarity and accuracy. First, I have standardized the use of abbreviations for Moringa oleifera (MO, MOE, and MOSE), following your recommendation to ensure consistency throughout the text. I have also corrected the discrepancy in the number of publications mentioned in the abstract, methods section, and reference list, ensuring uniformity in the data presented. Furthermore, I have thoroughly reviewed the English grammar and sentence structure as you suggested, to enhance the flow and readability of the manuscript. Additionally, I have checked and corrected the duplicated references you pointed out, ensuring accuracy and consistency in citation. Thank you once again for your attention to detail. Your feedback has been extremely helpful in improving the quality of the manuscript. Sincerely, Carlos Competing Interests: The authors declare that they have no competing interests. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 05 Feb 2025 C. A. Zuniga-Gonzalez , Area of knowledge of Agrarian and Veterinary Sciences. Agroecology, National Autonomous University of Nicaragua, Leon, Leon, 21000, Nicaragua 05 Feb 2025 Author Response Dear Reviewer 3, I sincerely appreciate your valuable feedback and observations. I have carefully reviewed your suggestions and made the necessary revisions in version 2 of the manuscript to improve ... Continue reading Dear Reviewer 3, I sincerely appreciate your valuable feedback and observations. I have carefully reviewed your suggestions and made the necessary revisions in version 2 of the manuscript to improve its clarity and accuracy. First, I have standardized the use of abbreviations for Moringa oleifera (MO, MOE, and MOSE), following your recommendation to ensure consistency throughout the text. I have also corrected the discrepancy in the number of publications mentioned in the abstract, methods section, and reference list, ensuring uniformity in the data presented. Furthermore, I have thoroughly reviewed the English grammar and sentence structure as you suggested, to enhance the flow and readability of the manuscript. Additionally, I have checked and corrected the duplicated references you pointed out, ensuring accuracy and consistency in citation. Thank you once again for your attention to detail. Your feedback has been extremely helpful in improving the quality of the manuscript. Sincerely, Carlos Dear Reviewer 3, I sincerely appreciate your valuable feedback and observations. I have carefully reviewed your suggestions and made the necessary revisions in version 2 of the manuscript to improve its clarity and accuracy. First, I have standardized the use of abbreviations for Moringa oleifera (MO, MOE, and MOSE), following your recommendation to ensure consistency throughout the text. I have also corrected the discrepancy in the number of publications mentioned in the abstract, methods section, and reference list, ensuring uniformity in the data presented. Furthermore, I have thoroughly reviewed the English grammar and sentence structure as you suggested, to enhance the flow and readability of the manuscript. Additionally, I have checked and corrected the duplicated references you pointed out, ensuring accuracy and consistency in citation. Thank you once again for your attention to detail. Your feedback has been extremely helpful in improving the quality of the manuscript. Sincerely, Carlos Competing Interests: The authors declare that they have no competing interests. Close Report a concern COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Osorio-Acosta F. Reviewer Report For: Biological properties of Moringa oleifera : A systematic review of the last decade [version 2; peer review: 3 approved] . F1000Research 2025, 13 :1390 ( https://doi.org/10.5256/f1000research.172612.r355204 ) The direct URL for this report is: https://f1000research.com/articles/13-1390/v1#referee-response-355204 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 16 Jan 2025 Francisco Osorio-Acosta , Veracruz campus, Veracruz, Mexico Approved VIEWS 0 https://doi.org/10.5256/f1000research.172612.r355204 The paper has an extensive review and explained properly, however it is necessary an English redaction review. The first paragraph in introduction require connection between ideas. Some scientific names are no correctly written (italics are not used), They used a ... Continue reading READ ALL The paper has an extensive review and explained properly, however it is necessary an English redaction review. The first paragraph in introduction require connection between ideas. Some scientific names are no correctly written (italics are not used), They used a lot of abbreviations, however they don't use or are used just once (MO), furthermore, there are abbreviations that mean the same but are different (MOLE and MOLEE as an example). It is necessary to review all. Page 4. Figure 1 is cited in the text, however does no correspond with the information present, should be placed in other paragraph. Page 4, 1.3. They don't include bibliography in a paragraph. Page 7. 3.2 Correct Atalas, and correct redaction (The seeds of Moringa oleifera seeds have also shown potential...) It should be expected that authors propose better future perspectives. Are the rationale for, and objectives of, the Systematic Review clearly stated? Yes Are sufficient details of the methods and analysis provided to allow replication by others? Yes Is the statistical analysis and its interpretation appropriate? Not applicable Are the conclusions drawn adequately supported by the results presented in the review? Partly If this is a Living Systematic Review, is the ‘living’ method appropriate and is the search schedule clearly defined and justified? (‘Living Systematic Review’ or a variation of this term should be included in the title.) Yes Competing Interests: No competing interests were disclosed. Reviewer Expertise: Plant pathology and use of different control methods, as plant extracts. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Osorio-Acosta F. Reviewer Report For: Biological properties of Moringa oleifera : A systematic review of the last decade [version 2; peer review: 3 approved] . F1000Research 2025, 13 :1390 ( https://doi.org/10.5256/f1000research.172612.r355204 ) The direct URL for this report is: https://f1000research.com/articles/13-1390/v1#referee-response-355204 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 30 Jan 2025 C. A. Zuniga-Gonzalez , Area of knowledge of Agrarian and Veterinary Sciences. Agroecology, National Autonomous University of Nicaragua, Leon, Leon, 21000, Nicaragua 30 Jan 2025 Author Response Thank you very much for your thorough review and constructive comments. We greatly appreciate your suggestions, and we have addressed all of the points you raised. The English writing has ... Continue reading Thank you very much for your thorough review and constructive comments. We greatly appreciate your suggestions, and we have addressed all of the points you raised. The English writing has been revised for better clarity and connection between ideas, and we have corrected the use of scientific names, ensuring proper italics are used. We have also reviewed and standardized the abbreviations throughout the paper, making sure they are consistently applied. Regarding the issues with Figure 1, it has been moved to the appropriate section. Additionally, we included the necessary bibliography in the 1.3 section and corrected the redaction in section 3.2, as you suggested. All these improvements have been made to enhance the overall quality of the manuscript. Thank you very much for your thorough review and constructive comments. We greatly appreciate your suggestions, and we have addressed all of the points you raised. The English writing has been revised for better clarity and connection between ideas, and we have corrected the use of scientific names, ensuring proper italics are used. We have also reviewed and standardized the abbreviations throughout the paper, making sure they are consistently applied. Regarding the issues with Figure 1, it has been moved to the appropriate section. Additionally, we included the necessary bibliography in the 1.3 section and corrected the redaction in section 3.2, as you suggested. All these improvements have been made to enhance the overall quality of the manuscript. Competing Interests: The authors declare no competing interests. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 30 Jan 2025 C. A. Zuniga-Gonzalez , Area of knowledge of Agrarian and Veterinary Sciences. Agroecology, National Autonomous University of Nicaragua, Leon, Leon, 21000, Nicaragua 30 Jan 2025 Author Response Thank you very much for your thorough review and constructive comments. We greatly appreciate your suggestions, and we have addressed all of the points you raised. The English writing has ... Continue reading Thank you very much for your thorough review and constructive comments. We greatly appreciate your suggestions, and we have addressed all of the points you raised. The English writing has been revised for better clarity and connection between ideas, and we have corrected the use of scientific names, ensuring proper italics are used. We have also reviewed and standardized the abbreviations throughout the paper, making sure they are consistently applied. Regarding the issues with Figure 1, it has been moved to the appropriate section. Additionally, we included the necessary bibliography in the 1.3 section and corrected the redaction in section 3.2, as you suggested. All these improvements have been made to enhance the overall quality of the manuscript. Thank you very much for your thorough review and constructive comments. We greatly appreciate your suggestions, and we have addressed all of the points you raised. The English writing has been revised for better clarity and connection between ideas, and we have corrected the use of scientific names, ensuring proper italics are used. We have also reviewed and standardized the abbreviations throughout the paper, making sure they are consistently applied. Regarding the issues with Figure 1, it has been moved to the appropriate section. Additionally, we included the necessary bibliography in the 1.3 section and corrected the redaction in section 3.2, as you suggested. All these improvements have been made to enhance the overall quality of the manuscript. Competing Interests: The authors declare no competing interests. Close Report a concern COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Carvajal Alcaraz M. Reviewer Report For: Biological properties of Moringa oleifera : A systematic review of the last decade [version 2; peer review: 3 approved] . F1000Research 2025, 13 :1390 ( https://doi.org/10.5256/f1000research.172612.r342878 ) The direct URL for this report is: https://f1000research.com/articles/13-1390/v1#referee-response-342878 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 14 Dec 2024 Micaela Carvajal Alcaraz , CEBAS-CSIC. Campus Universitario de Espinardo, Murcia, Spain Approved with Reservations VIEWS 0 https://doi.org/10.5256/f1000research.172612.r342878 This work reviews the biological activities of Moringa oleifera , highlighting its antitumor, antimicrobial, and protective effects against metabolic, infectious, and chronic diseases, based on evidence from 129 studies published between 2010 and 2021. The review explores Moringa oleifera across various ... Continue reading READ ALL This work reviews the biological activities of Moringa oleifera , highlighting its antitumor, antimicrobial, and protective effects against metabolic, infectious, and chronic diseases, based on evidence from 129 studies published between 2010 and 2021. The review explores Moringa oleifera across various fields, including medicine and biotechnology, highlighting its versatility and addressing a wide range of bioactivities, including antioxidant, antitumor, antimicrobial, and organ-protective effects, underscoring its therapeutic potential. The reviewed findings open avenues for further exploration into drug development and integrative health strategies involving Moringa oleifera . POINTS 2.- I have notice that there are some other reviews already published with similar subject: SJ Stohs, MJ Hartman. Review of the Safety and Efficacy of Moringa oleifera- Phytotherapy Research, 2015 (Ref-1) - Wiley Online Library KT Mahmood, T Mugal, IU Haq. Moringa oleifera: a natural gift-A review- Journal of Pharmaceutical …, 2010 NZ Abd Rani, K Husain, E Kumolosasi. Moringa Genus: A Review of Phytochemistry and Pharmacology. - Frontiers in pharmacology, 2018 (Ref-2) - frontiersin.org L Gopalakrishnan, K Doriya, DS Kumar. Moringa oleifera: A review on nutritive importance and its medicinal application.- Food science and human …, 2016 (Ref-3) - Elsevier Therefore, the novelty of this actual one should be highlight and clearly establish the added value and relevance compared to previous works. I suggest the following: -Highlight that your review specifically examines the dual potential of Moringa oleifera i n tackling both cancer and antimicrobial resistance—two critical and globally relevant health challenges. Also that it integrates data from diverse fields such as medicine, biotechnology, and phytotherapy, offering a broader perspective than reviews focused solely on one discipline. -The review should highlight any newly identified mechanisms, pathways, or potential clinical applications of Moringa oleifera that may not have been discussed extensively in prior reviews. 2.- The conclusions might overstate the potential of Moringa oleifera without sufficient caution about its limitations, such as possible toxicity, variability in efficacy, or challenges in standardizing extracts. This fact should be implemented in discussion or conclusions. Are the rationale for, and objectives of, the Systematic Review clearly stated? Yes Are sufficient details of the methods and analysis provided to allow replication by others? Yes Is the statistical analysis and its interpretation appropriate? Not applicable Are the conclusions drawn adequately supported by the results presented in the review? Yes If this is a Living Systematic Review, is the ‘living’ method appropriate and is the search schedule clearly defined and justified? (‘Living Systematic Review’ or a variation of this term should be included in the title.) Not applicable References 1. Stohs SJ, Hartman MJ: Review of the Safety and Efficacy of Moringa oleifera. Phytother Res . 2015; 29 (6): 796-804 PubMed Abstract | Publisher Full Text 2. Abd Rani NZ, Husain K, Kumolosasi E: Moringa Genus: A Review of Phytochemistry and Pharmacology. Front Pharmacol . 2018; 9 : 108 PubMed Abstract | Publisher Full Text 3. Gopalakrishnan L, Doriya K, Kumar D: Moringa oleifera: A review on nutritive importance and its medicinal application. Food Science and Human Wellness . 2016; 5 (2): 49-56 Publisher Full Text Competing Interests: No competing interests were disclosed. Reviewer Expertise: Plant Sciences I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Carvajal Alcaraz M. Reviewer Report For: Biological properties of Moringa oleifera : A systematic review of the last decade [version 2; peer review: 3 approved] . F1000Research 2025, 13 :1390 ( https://doi.org/10.5256/f1000research.172612.r342878 ) The direct URL for this report is: https://f1000research.com/articles/13-1390/v1#referee-response-342878 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 30 Jan 2025 C. A. Zuniga-Gonzalez , Area of knowledge of Agrarian and Veterinary Sciences. Agroecology, National Autonomous University of Nicaragua, Leon, Leon, 21000, Nicaragua 30 Jan 2025 Author Response We sincerely thank the reviewer for their insightful and constructive feedback, which has significantly contributed to improving the quality of our manuscript. Your suggestions to clearly emphasize the novelty and ... Continue reading We sincerely thank the reviewer for their insightful and constructive feedback, which has significantly contributed to improving the quality of our manuscript. Your suggestions to clearly emphasize the novelty and added value of our review compared to existing literature and to address the limitations of Moringa oleifera have been invaluable. These recommendations will guide us in refining our analysis and ensuring a balanced presentation of findings. We sincerely thank the reviewer for their insightful and constructive feedback, which has significantly contributed to improving the quality of our manuscript. Your suggestions to clearly emphasize the novelty and added value of our review compared to existing literature and to address the limitations of Moringa oleifera have been invaluable. These recommendations will guide us in refining our analysis and ensuring a balanced presentation of findings. Competing Interests: The authors declare no competing interests. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 30 Jan 2025 C. A. Zuniga-Gonzalez , Area of knowledge of Agrarian and Veterinary Sciences. Agroecology, National Autonomous University of Nicaragua, Leon, Leon, 21000, Nicaragua 30 Jan 2025 Author Response We sincerely thank the reviewer for their insightful and constructive feedback, which has significantly contributed to improving the quality of our manuscript. Your suggestions to clearly emphasize the novelty and ... Continue reading We sincerely thank the reviewer for their insightful and constructive feedback, which has significantly contributed to improving the quality of our manuscript. Your suggestions to clearly emphasize the novelty and added value of our review compared to existing literature and to address the limitations of Moringa oleifera have been invaluable. These recommendations will guide us in refining our analysis and ensuring a balanced presentation of findings. We sincerely thank the reviewer for their insightful and constructive feedback, which has significantly contributed to improving the quality of our manuscript. Your suggestions to clearly emphasize the novelty and added value of our review compared to existing literature and to address the limitations of Moringa oleifera have been invaluable. These recommendations will guide us in refining our analysis and ensuring a balanced presentation of findings. Competing Interests: The authors declare no competing interests. Close Report a concern COMMENT ON THIS REPORT Comments on this article Comments (0) Version 2 VERSION 2 PUBLISHED 19 Nov 2024 ADD YOUR COMMENT Comment keyboard_arrow_left keyboard_arrow_right Open Peer Review Reviewer Status info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Reviewer Reports Invited Reviewers 1 2 3 Version 2 (revision) 30 Jan 25 read Version 1 19 Nov 24 read read read Micaela Carvajal Alcaraz , CEBAS-CSIC. Campus Universitario de Espinardo, Murcia, Spain Francisco Osorio-Acosta , Veracruz campus, Veracruz, Mexico Pradeep Singh , Debre Tabor University, Debre Tabor, Ethiopia Comments on this article All Comments (0) Add a comment Sign up for content alerts Sign Up You are now signed up to receive this alert Browse by related subjects keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2025 Carvajal Alcaraz M. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 22 Feb 2025 | for Version 2 Micaela Carvajal Alcaraz , CEBAS-CSIC. Campus Universitario de Espinardo, Murcia, Spain 0 Views copyright © 2025 Carvajal Alcaraz M. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions The authors have thoroughly addressed all concerns raised in the manuscript. Specifically, they have clearly established the novelty and added value of this review by emphasizing its unique focus on the dual potential of Moringa oleifera in combating both cancer and antimicrobial resistance. Additionally, they have integrated data from multiple disciplines, including medicine, biotechnology, and phytotherapy, providing a broader perspective than previous reviews. The discussion has been expanded to highlight newly identified mechanisms, pathways, and potential clinical applications not extensively covered in prior literature. Furthermore, the conclusions have been revised to ensure a balanced perspective, incorporating a discussion of possible limitations such as toxicity, variability in efficacy, and challenges in standardizing extracts. Competing Interests No competing interests were disclosed. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (0) Carvajal Alcaraz M. Peer Review Report For: Biological properties of Moringa oleifera : A systematic review of the last decade [version 2; peer review: 3 approved] . F1000Research 2025, 13 :1390 ( https://doi.org/10.5256/f1000research.177200.r363555) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/13-1390/v2#referee-response-363555 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2025 Singh P. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 30 Jan 2025 | for Version 1 Pradeep Singh , Debre Tabor University, Debre Tabor, Amhara, Ethiopia 0 Views copyright © 2025 Singh P. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Biological properties of Moringa oleifera : A systematic review of the last decade This review examines original research papers on Moringa oleifera published from 2010 to 2021. The papers focus on biological properties, especially antitumor activity and possible uses against chronic and infectious diseases. The authors gave in-depth pharmacognostical descriptions and phytochemicals from different parts of Moringa oleifera. They also talked about the plant's traditional uses, antioxidant effects, and potential to fight cancer. activity. The systematic review is compiled by collecting original research articles from various databases like PubMed, Scopus, and Google Scholar. The method used to put this together was very detailed. First, 2700 publications were found in databases. These were then screened to find 410 articles that met certain criteria, such as having to do with Moringa oleifera, chronic diseases, infectious diseases, biological activity, human cancer, antitumor biological activity, in vivo and in vitro activity, and anticancer properties. Finally, 129 (134 listed in reference section) publications were chosen to be included in the final draft of the systematic review. This compilation excludes previously published reviews, editorials, and articles published in languages other than English and Spanish. Suggestions Abbreviations like MO, MOE, and MOSE for Moringa oleifera should be used wisely, and uniformity must be maintained throughout the article. Authors can use an abbreviation once at the beginning of the article with a full description, and then only use the abbreviation for further references. The numbers of publications used for this compilation should be the same. Please check 129 publications mentioned in the abstract, 112 written in the second paragraph of the method section, and a total of 134 references listed under the reference section. Authors must review English grammar and sentence construction. As mentioned below, recheck references for duplication. 129. Soto AJ, Gomez AC, Vasquez BM, et al. : A Biological properties of Moringa oleifera: a review in the last decade. Publisher Full Text 134. Soto JA, Gomez AC, Vásquez BM, et al. : Data for Biological properties of Moringa oleifera: a review in last decade. Dataset. figshare. 2024. Publisher Full Text Are the rationale for, and objectives of, the Systematic Review clearly stated? Yes Are sufficient details of the methods and analysis provided to allow replication by others? Yes Is the statistical analysis and its interpretation appropriate? Not applicable Are the conclusions drawn adequately supported by the results presented in the review? Yes If this is a Living Systematic Review, is the ‘living’ method appropriate and is the search schedule clearly defined and justified? (‘Living Systematic Review’ or a variation of this term should be included in the title.) No Competing Interests No competing interests were disclosed. Reviewer Expertise Pharmacognosy & Phytochemistry I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (1) Author Response 05 Feb 2025 C. A. Zuniga-Gonzalez, Area of knowledge of Agrarian and Veterinary Sciences. Agroecology, National Autonomous University of Nicaragua, Leon, Leon, 21000, Nicaragua Dear Reviewer 3, I sincerely appreciate your valuable feedback and observations. I have carefully reviewed your suggestions and made the necessary revisions in version 2 of the manuscript to improve its clarity and accuracy. First, I have standardized the use of abbreviations for Moringa oleifera (MO, MOE, and MOSE), following your recommendation to ensure consistency throughout the text. I have also corrected the discrepancy in the number of publications mentioned in the abstract, methods section, and reference list, ensuring uniformity in the data presented. Furthermore, I have thoroughly reviewed the English grammar and sentence structure as you suggested, to enhance the flow and readability of the manuscript. Additionally, I have checked and corrected the duplicated references you pointed out, ensuring accuracy and consistency in citation. Thank you once again for your attention to detail. Your feedback has been extremely helpful in improving the quality of the manuscript. Sincerely, Carlos View more View less Competing Interests The authors declare that they have no competing interests. reply Respond Report a concern Singh P. Peer Review Report For: Biological properties of Moringa oleifera : A systematic review of the last decade [version 2; peer review: 3 approved] . F1000Research 2025, 13 :1390 ( https://doi.org/10.5256/f1000research.172612.r355211) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/13-1390/v1#referee-response-355211 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2025 Osorio-Acosta F. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 16 Jan 2025 | for Version 1 Francisco Osorio-Acosta , Veracruz campus, Veracruz, Mexico 0 Views copyright © 2025 Osorio-Acosta F. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions The paper has an extensive review and explained properly, however it is necessary an English redaction review. The first paragraph in introduction require connection between ideas. Some scientific names are no correctly written (italics are not used), They used a lot of abbreviations, however they don't use or are used just once (MO), furthermore, there are abbreviations that mean the same but are different (MOLE and MOLEE as an example). It is necessary to review all. Page 4. Figure 1 is cited in the text, however does no correspond with the information present, should be placed in other paragraph. Page 4, 1.3. They don't include bibliography in a paragraph. Page 7. 3.2 Correct Atalas, and correct redaction (The seeds of Moringa oleifera seeds have also shown potential...) It should be expected that authors propose better future perspectives. Are the rationale for, and objectives of, the Systematic Review clearly stated? Yes Are sufficient details of the methods and analysis provided to allow replication by others? Yes Is the statistical analysis and its interpretation appropriate? Not applicable Are the conclusions drawn adequately supported by the results presented in the review? Partly If this is a Living Systematic Review, is the ‘living’ method appropriate and is the search schedule clearly defined and justified? (‘Living Systematic Review’ or a variation of this term should be included in the title.) Yes Competing Interests No competing interests were disclosed. Reviewer Expertise Plant pathology and use of different control methods, as plant extracts. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (1) Author Response 30 Jan 2025 C. A. Zuniga-Gonzalez, Area of knowledge of Agrarian and Veterinary Sciences. Agroecology, National Autonomous University of Nicaragua, Leon, Leon, 21000, Nicaragua Thank you very much for your thorough review and constructive comments. We greatly appreciate your suggestions, and we have addressed all of the points you raised. The English writing has been revised for better clarity and connection between ideas, and we have corrected the use of scientific names, ensuring proper italics are used. We have also reviewed and standardized the abbreviations throughout the paper, making sure they are consistently applied. Regarding the issues with Figure 1, it has been moved to the appropriate section. Additionally, we included the necessary bibliography in the 1.3 section and corrected the redaction in section 3.2, as you suggested. All these improvements have been made to enhance the overall quality of the manuscript. View more View less Competing Interests The authors declare no competing interests. reply Respond Report a concern Osorio-Acosta F. Peer Review Report For: Biological properties of Moringa oleifera : A systematic review of the last decade [version 2; peer review: 3 approved] . F1000Research 2025, 13 :1390 ( https://doi.org/10.5256/f1000research.172612.r355204) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/13-1390/v1#referee-response-355204 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2024 Carvajal Alcaraz M. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 14 Dec 2024 | for Version 1 Micaela Carvajal Alcaraz , CEBAS-CSIC. Campus Universitario de Espinardo, Murcia, Spain 0 Views copyright © 2024 Carvajal Alcaraz M. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions This work reviews the biological activities of Moringa oleifera , highlighting its antitumor, antimicrobial, and protective effects against metabolic, infectious, and chronic diseases, based on evidence from 129 studies published between 2010 and 2021. The review explores Moringa oleifera across various fields, including medicine and biotechnology, highlighting its versatility and addressing a wide range of bioactivities, including antioxidant, antitumor, antimicrobial, and organ-protective effects, underscoring its therapeutic potential. The reviewed findings open avenues for further exploration into drug development and integrative health strategies involving Moringa oleifera . POINTS 2.- I have notice that there are some other reviews already published with similar subject: SJ Stohs, MJ Hartman. Review of the Safety and Efficacy of Moringa oleifera- Phytotherapy Research, 2015 (Ref-1) - Wiley Online Library KT Mahmood, T Mugal, IU Haq. Moringa oleifera: a natural gift-A review- Journal of Pharmaceutical …, 2010 NZ Abd Rani, K Husain, E Kumolosasi. Moringa Genus: A Review of Phytochemistry and Pharmacology. - Frontiers in pharmacology, 2018 (Ref-2) - frontiersin.org L Gopalakrishnan, K Doriya, DS Kumar. Moringa oleifera: A review on nutritive importance and its medicinal application.- Food science and human …, 2016 (Ref-3) - Elsevier Therefore, the novelty of this actual one should be highlight and clearly establish the added value and relevance compared to previous works. I suggest the following: -Highlight that your review specifically examines the dual potential of Moringa oleifera i n tackling both cancer and antimicrobial resistance—two critical and globally relevant health challenges. Also that it integrates data from diverse fields such as medicine, biotechnology, and phytotherapy, offering a broader perspective than reviews focused solely on one discipline. -The review should highlight any newly identified mechanisms, pathways, or potential clinical applications of Moringa oleifera that may not have been discussed extensively in prior reviews. 2.- The conclusions might overstate the potential of Moringa oleifera without sufficient caution about its limitations, such as possible toxicity, variability in efficacy, or challenges in standardizing extracts. This fact should be implemented in discussion or conclusions. Are the rationale for, and objectives of, the Systematic Review clearly stated? Yes Are sufficient details of the methods and analysis provided to allow replication by others? Yes Is the statistical analysis and its interpretation appropriate? Not applicable Are the conclusions drawn adequately supported by the results presented in the review? Yes If this is a Living Systematic Review, is the ‘living’ method appropriate and is the search schedule clearly defined and justified? (‘Living Systematic Review’ or a variation of this term should be included in the title.) Not applicable References 1. Stohs SJ, Hartman MJ: Review of the Safety and Efficacy of Moringa oleifera. Phytother Res . 2015; 29 (6): 796-804 PubMed Abstract | Publisher Full Text 2. Abd Rani NZ, Husain K, Kumolosasi E: Moringa Genus: A Review of Phytochemistry and Pharmacology. Front Pharmacol . 2018; 9 : 108 PubMed Abstract | Publisher Full Text 3. Gopalakrishnan L, Doriya K, Kumar D: Moringa oleifera: A review on nutritive importance and its medicinal application. Food Science and Human Wellness . 2016; 5 (2): 49-56 Publisher Full Text Competing Interests No competing interests were disclosed. Reviewer Expertise Plant Sciences I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. reply Respond to this report Responses (1) Author Response 30 Jan 2025 C. A. Zuniga-Gonzalez, Area of knowledge of Agrarian and Veterinary Sciences. Agroecology, National Autonomous University of Nicaragua, Leon, Leon, 21000, Nicaragua We sincerely thank the reviewer for their insightful and constructive feedback, which has significantly contributed to improving the quality of our manuscript. Your suggestions to clearly emphasize the novelty and added value of our review compared to existing literature and to address the limitations of Moringa oleifera have been invaluable. These recommendations will guide us in refining our analysis and ensuring a balanced presentation of findings. View more View less Competing Interests The authors declare no competing interests. reply Respond Report a concern Carvajal Alcaraz M. Peer Review Report For: Biological properties of Moringa oleifera : A systematic review of the last decade [version 2; peer review: 3 approved] . F1000Research 2025, 13 :1390 ( https://doi.org/10.5256/f1000research.172612.r342878) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/13-1390/v1#referee-response-342878 Alongside their report, reviewers assign a status to the article: Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions Adjust parameters to alter display View on desktop for interactive features Includes Interactive Elements View on desktop for interactive features Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Stay Updated Sign up for content alerts and receive a weekly or monthly email with all newly published articles Register with F1000Research Already registered? Sign in Not now, thanks close PLEASE NOTE If you are an AUTHOR of this article, please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a “User Comment”. If you are a REVIEWER of this article, please check that you have signed in with the account associated with this article and then go to your account to submit your report, please do not post your review here. If you do not have access to your original account, please contact us . All commenters must hold a formal affiliation as per our Policies . The information that you give us will be displayed next to your comment. User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions . Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available. I accept the User Comment Terms and Conditions Please confirm that you accept the User Comment Terms and Conditions. Affiliation ✕ refresh Please enter your institution. Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name. If the name does not appear in the drop-down list, we will display the information you have entered. ✕ refresh Country/Region * USA UK Canada China France Germany Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Federated States of Micronesia Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo (Serbia and Montenegro) Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Minor Outlying Islands of the United States Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea North Macedonia Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Is South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand The Gambia The Netherlands Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu UK USA Uganda Ukraine United Arab Emirates United States Virgin Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Wallis and Futuna West Bank and Gaza Strip Western Sahara Yemen Zambia Zimbabwe Please select your country/region. You must enter a comment. Competing Interests Please disclose any competing interests that might be construed to influence your judgment of the article's or peer review report's validity or importance. Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Please state your competing interests The comment has been saved. An error has occurred. Please try again. Cancel Post var lTitle = "Biological properties of Moringa oleifera:...".replace("'", ''); var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/13-1390/v2" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by '); var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/13-1390/v2&title=" + encodeURIComponent(lTitle); var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/13-1390/v2" + "&title=" + encodeURIComponent(lTitle); linkedInUrl += encodeURIComponent('Soto JA et al.'); var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; var addthis_config = { ui_offset_top: offsetTop, services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_custom : [ { name: "LinkedIn", url: linkedInUrl, icon:"/img/icon/at_linkedin.svg" }, { name: "Mendeley", url: "http://www.mendeley.com/import/?url=https://f1000research.com/articles/13-1390/v2/mendeley", icon:"/img/icon/at_mendeley.svg" }, { name: "Reddit", url: redditUrl, icon:"/img/icon/at_reddit.svg" }, ] }; var addthis_share = { url: "https://f1000research.com/articles/13-1390", templates : { twitter : "Biological properties of Moringa oleifera: A systematic review.... Soto JA et al., published by " + "@F1000Research" + ", https://f1000research.com/articles/13-1390/v2" } }; if (typeof(addthis) != "undefined"){ addthis.addEventListener('addthis.ready', checkCount); addthis.addEventListener('addthis.menu.share', checkCount); } $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter); $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url); $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url); $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url); $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url); function checkCount(){ setTimeout(function(){ $(".addthis_button_expanded").each(function(){ var count = $(this).text(); if (count !== "" && count != "0") $(this).removeClass("is-hidden"); else $(this).addClass("is-hidden"); }); }, 1000); } close How to cite this report {{reportCitation}} Cancel Copy Citation Details $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');}); $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');}); $.get("/articles/acj/157194/177200") new F1000.Clipboard(); new F1000.ThesaurusTermsDisplay("articles", "article", "177200"); $(document).ready(function() { $( "#frame1" ).on('load', function() { var mydiv = $(this).contents().find("div"); var h = mydiv.height(); console.log(h) }); var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"), titleLivingFigure = tooltipLivingFigure.attr("title"); tooltipLivingFigure.simpletip({ fixed: true, position: ["-115", "30"], baseClass: 'small-tooltip', content:titleLivingFigure + " " }); tooltipLivingFigure.removeAttr("title"); $("body").on("click", ".cite-living-figure", function(e) { e.preventDefault(); var ref = $(this).attr("data-ref"); $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200); }); $("body").on("click", ".close-cite-living-figure", function(e) { e.preventDefault(); $(this).closest(".popup-window-wrapper").fadeOut(200); }); $(document).on("mouseup", function(e) { var metricsContainer = $(".article-metrics-popover-wrapper"); if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) { $(".article-metrics-close-button").click(); } }); var articleId = $('#articleId').val(); if($("#main-article-count-box").attachArticleMetrics) { $("#main-article-count-box").attachArticleMetrics(articleId, { articleMetricsView: true }); } }); var figshareWidget = $(".new_figshare_widget"); if (figshareWidget.length > 0) { window.figshare.load("f1000", function(Widget) { // Select a tag/tags defined in your page. In this tag we will place the widget. _.map(figshareWidget, function(el){ var widget = new Widget({ articleId: $(el).attr("figshare_articleId") //height:300 // this is the height of the viewer part. [Default: 550] }); widget.initialize(); // initialize the widget widget.mount(el); // mount it in a tag that's on your page // this will save the widget on the global scope for later use from // your JS scripts. This line is optional. //window.widget = widget; }); }); } close Error Close Add Reset F1000.MICROSERVICES.AFFILIATION = ''; $(document).ready(function () { $('.js-affiliations-form').each((index, form) => { new AffiliationForm({ formId: form.id, institutionErrorSelector: '.comment-enter-institution', departmentErrorSelector: '.comment-enter-department', placeSelector: '.js-add-comment-place', stateSelector: '.js-add-comment-state', zipCodeSelector: '.js-add-comment-zipcode', countrySelector: '.js-add-comment-country', countryErrorSelector: '.comment-enter-country', }); }); }); $(document).ready(function () { var reportIds = { "355205": 0, "355204": 11, "355207": 0, "355206": 0, "355203": 0, "355212": 0, "355209": 0, "355208": 0, "355211": 11, "355210": 0, "345813": 0, "345812": 0, "345815": 0, "345814": 0, "345811": 0, "345810": 0, "342877": 0, "342876": 0, "342879": 0, "342878": 19, "345817": 0, "345816": 0, "342875": 0, "345819": 0, "342874": 0, "345818": 0, "363557": 0, "352997": 0, "363556": 0, "352999": 0, "352998": 0, "342881": 0, "342880": 0, "363555": 6, "342883": 0, "342882": 0, "353005": 0, "353004": 0, "353006": 0, "353001": 0, "353000": 0, "353003": 0, "353002": 0, }; $(".referee-response-container,.js-referee-report").each(function(index, el) { var reportId = $(el).attr("data-reportid"), reportCount = reportIds[reportId] || 0; $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount); }); var uuidInput = $("#article_uuid"), oldUUId = uuidInput.val(), newUUId = "a787d328-5239-479b-91c3-ed03a3caf7b7"; uuidInput.val(newUUId); $("a[href*='article_uuid=']").each(function(index, el) { var newHref = $(el).attr("href").replace(oldUUId, newUUId); $(el).attr("href", newHref); }); }); An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing. Browse Gateways Collections How it Works Contact For Developers Cookie Notice Privacy Notice RSS Submit Your Research Follow us © 2012-2026 F1000 Research Ltd. ISSN 2046-1402 | Legal | Partner of Research4Life • CrossRef • ORCID • FAIRSharing R.templateTests.simpleTemplate = R.template(' $text $text $text $text $text '); R.templateTests.runTests(); var F1000platform = new F1000.Platform({ name: "f1000research", displayName: "F1000Research", hostName: "f1000research.com", id: "1", editorialEmail: "[email protected]", infoEmail: "[email protected]", usePmcStats: true }); $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');}); // $(function(){R.ui.dropdowns('.dropdown-for-referees');}); $(document).ready(function () { if ($(".cookie-warning").is(":visible")) { $(".sticky").css("margin-bottom", "35px"); $(".devices").addClass("devices-and-cookie-warning"); } $(".cookie-warning .close-button").click(function (e) { $(".devices").removeClass("devices-and-cookie-warning"); $(".sticky").css("margin-bottom", "0"); }); $("#tweeter-feed .tweet-message").each(function (i, message) { var self = $(message); self.html(linkify(self.html())); }); $(".partner").on("mouseenter mouseleave", function() { $(this).find(".gray-scale, .colour").toggleClass("is-hidden"); }); }); Sign In Remember me Forgotten your password? Sign In Cancel Email or password not correct. Please try again Please wait... $(function(){ // Note: All the setup needs to run against a name attribute and *not* the id due the clonish // nature of facebox... $("a[id=googleSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("GOOGLE"); $("form[id=oAuthForm]").submit(); }); $("a[id=facebookSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("FACEBOOK"); $("form[id=oAuthForm]").submit(); }); $("a[id=orcidSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("ORCID"); $("form[id=oAuthForm]").submit(); }); }); If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password. The email address should be the one you originally registered with F1000. Email address not valid, please try again You registered with F1000 via Google, so we cannot reset your password. To sign in, please click here . If you still need help with your Google account password, please click here . You registered with F1000 via Facebook, so we cannot reset your password. To sign in, please click here . If you still need help with your Facebook account password, please click here . Code not correct, please try again Reset password Cancel Email us for further assistance. Server error, please try again. If your email address is registered with us, we will email you instructions to reset your password. If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance. Please wait... Register $(document).ready(function () { signIn.createSignInAsRow($("#sign-in-form-gfb-popup")); $(".target-field").each(function () { var uris = $(this).val().split("/"); if (uris.pop() === "login") { $(this).val(uris.toString().replace(",","/")); } }); });